Archive for the ‘Scientist: Career considerations’ Category

Cancer Labs at School of Medicine @ Technion: Janet and David Polak Cancer and Vascular Biology Research Center

Posted in Academic Publishing, Autologous Cell Therapy, Bio Instrumentation in Experimental Life Sciences Research, BioBanking, Biological Networks, Gene Regulation and Evolution, Biomarkers & Medical Diagnostics, Biomedical Measurement Science, BioSimilars, CANCER BIOLOGY & Innovations in Cancer Therapy, Cardiac muscle regeneration, Cardiovascular Pharmacogenomics, Cell Biology, Signaling & Cell Circuits, Chemical Biology and its relations to Metabolic Disease, Chemical Genetics, Circulating Progenitor Cells, Computational Biology/Systems and Bioinformatics, Cytoskeleton, Diagnostic Immunology, Drug Delivery Platform Technology, Drug Toxicity, Frontiers in Cardiology and Cardiovascular Disorders, Genome Biology, Genomic Testing: Methodology for Diagnosis, Human Immune System in Health and in Disease, Immunodiagnostics, Innovation in Immunology Diagnostics, Intellectual Property, Innovations, Commercialization, Investment in technological breakthrough, Interviews with Scientific Leaders, Personalized and Precision Medicine & Genomic Research, Pharmaceutical Analytics, Pharmaceutical R&D Investment, Pharmacogenomics, Pharmacologic toxicities, Population Health Management, Genetics & Pharmaceutical, Proteomics, Regenerative Biology and Medicine, Regulated Clinical Trials: Design, Methods, Components and IRB related issues, Scientist: Career considerations, Signaling, Stem Cells for Regenerative Medicine, Technology Transfer: Biotech and Pharmaceutical, Translational Science, Ubiquitinylation on May 28, 2014| Leave a Comment »

Cancer Labs at School of Medicine @ Technion

Reporter: Aviva Lev-Ari, PhD, RN

Article ID #139: Cancer Labs at School of Medicine @ Technion: Janet and David Polak Cancer and Vascular Biology Research Center. Published on 5/28/2014

WordCloud Image Produced by Adam Tubman

Janet and David Polak Cancer and Vascular Biology Research Center. The Rappaport Faculty of Medicine Research Institute and Faculty of Medicine, Technion – Israel Institute of Technology, Haifa, Israel

The center was established in 2003 to promote an in-depth interdisciplinary basic and clinical research on the control of cellular and molecular processes that are involved in cancer initiation and progression. We strongly believe that the understanding of basic biological processes that underlie normal development and their deregulation in cancer, is crucial for our ability to identify molecular targets for early detection, intervention, and cure of the disease. We are interested in a broad view of cancer – from the single malignantly transformed cell and its microenvironment, through the entire tumor in the animal. We focus on targeted ubiquitin-mediated degradation of key regulatory proteins that are involved in malignant transformation [Prof. Aaron Ciechanover (Nobel Prize in Chemistry 2004)], angiogenesis and cancer progression (Prof. Gera Neufeld), metastasis and tumor microenvironment (Prof. Israel Vlodavsky), as well as genetic and genomic dissection of embryonic and cancer transcriptional networks (Dr. Amir Orian). Towards these objectives, we combine molecular, biochemical, cell biological with Drosophila genetic and genomics experimental approaches, as well as employing advanced models of angiogenesis and metastasis.

We believe that scientific excellence and collegiality go together. Therefore, the center has an open and friendly atmosphere, creating a highly stimulating environment. The center is located in the 11th Floor of the Rappaport Faculty of Medicine building. It currently trains 45 graduate students, post-doctoral fellows, clinicians and researchers that are at the heart of our research. Formal and informal collaborations between individuals and laboratories are on-going and encouraged. We are running a series of joint seminars to which we invite researchers from Israel and abroad. The Center has advanced state-of-the-art microscopic and image analysis equipment, as well as other shared pieces of infrastructural equipment . The center is an integral part of the Faculty of Medicine and the Rappaport Research Institute which are home for excellent research groups, and enjoys their advanced Interdepartmental Equipment Unit. It is also adjacent to the Rambam Medical Center – the major hospital in the north of Israel – which provides us with access to rich clinical material and collaboration with clinicians. Many of them spend active research periods in our laboratories and bring the bench closer to the patient bed and vice versa. The Center is in an active phase of growth, and offers excellent research opportunities, space and facilities for students, post-doctoral fellows, and physicians.

Research Groups The Ubiquitin System and Cellular Protein Turnover and Interactions Immunity and Host Defense Cardiovascular Biology The Central Nervous System in Health and Disease Developmental Biology and Cancer Research Genetics

SOURCE 

http://www.rappaport.org.il/Rappaport/Templates/ShowPage.asp?DBID=1&TMID=842&FID=76

The cancer and vascular biology research center was established in 2003 to promote an in-depth interdisciplinary basic and clinical research on the control of cellular and molecular processes that are involved in cancer development and progression. Our goal is to advance knowledge in fundamental biological questions that are highly relevant for cancer.

	The cancer and vascular biology research center was established in 2003 to promote an in-depth interdisciplinary basic and clinical research on the control of cellular and molecular processes that are involved in cancer development and progression. Our goal is to advance knowledge in fundamental biological questions that are highly relevant for cancer.

SOURCE

http://www.technioncancer.co.il/index.php

Home  >>  Research Groups

Aaron Ciechanover Protein Turnover Intracellular protein degradation and mechanisms of cancer Israel Vlodavsky Cancer Biology Impact of heparanase and the tumor microenvironment on cancer progression: Basic aspects and clinical implications Gera Neufeld Tumor Progression & Angiogenesis Blood vessels and tumor progression: The neuropilin connection Amir Orian Genetic Networks Genetic networks in development and cancer

Home About the Cancer Centers Research Groups Administration / Contact Join – Us Seminars and Events Links Beyond Science Friends and supporters Ms. Sigal Alfasi – Izrael, Center’s coordinator e-mail: gsigal@tx.technion.ac.il Tel: +972-4-829-5424 Fax: +972-4-852-3947

SOURCE

http://www.technioncancer.co.il/ResearchGroups.php

Yuval Shaked, PhD

Publications by Yuval Shaked, PhD

Assistant Professor of Molecular Pharmacology

PhD, 2004 – Hebrew University, Israel

Understanding host – tumor interactions during cancer therapy

Personalized medicine holds promise of better cures with fewer side effects for many diseases. Individualized cancer therapy is sometimes utilized after multiple attempts of standard therapies and is based on several considerations, such as tumor type, acquired resistance to a specific therapy, previous treatment protocols, and other tumor-related factors. We have recently demonstrated that many cancer therapies can induce pro-tumorigenic or metastatic effects that derive not only from the tumor cells themselves, but also from host cells within the tumor microenvironment. The focus of research in my laboratory is to identify, characterize, and seek ways to block such pro-tumorigenic host effects observed after anti-cancer therapy, and thus potentially improve the outcome of current cancer therapies. Our findings may foster a paradigm shift in cancer therapy by minimizing the gap between preclinical findings and the clinical setting, laying the foundation for development of entirely new strategies for improving cancer therapy.

SOURCE

http://www.rappaport.org.il/Rappaport/Templates/ShowPage.asp?DBID=1&TMID=610&FID=77&PID=0&IID=1268

 

Other Related articled published on this Open Access Online Scientific Journal included the following:

D&D NT’s Solution: Galectin Proteins for Therapy and Diagnosis of Autoimmune Inflammatory and Cancer Diseases, Dr. Itshak Golan, CEO

http://pharmaceuticalintelligence.com/2014/05/28/dd-nts-solution-galectin-proteins-for-therapy-and-diagnosis-of-autoimmune-inflammatory-and-cancer-diseases-dr-itshak-golan-ceo/

MaimoniDex RA:  Monoclonal Antibodies for Therapy and Diagnosis of Cancer and Autoimmune Inflammatory Diseases – Dr. Itshak Golan, CEO

http://pharmaceuticalintelligence.com/2014/05/28/maimonidex-ra-monoclonal-antibodies-for-therapy-and-diagnosis-of-cancer-and-autoimmune-inflammatory-diseases-dr-itshak-golan-ceo/

Share this:

• X
• LinkedIn
• Facebook
• Print
• Email

Like this:

Like Loading…

Read Full Post »

Immunity and Host Defense – A Bibliography of Research @Technion

Posted in Biological Networks, Gene Regulation and Evolution, Biomarkers & Medical Diagnostics, Biomedical Measurement Science, CANCER BIOLOGY & Innovations in Cancer Therapy, Cancer Prevention: Research & Programs, Cell Biology, Signaling & Cell Circuits, Chemical Biology and its relations to Metabolic Disease, Chemical Genetics, Diagnostic Immunology, Drug Delivery Platform Technology, Drug Toxicity, FDA Regulatory Affairs, Genome Biology, Genomic Testing: Methodology for Diagnosis, Human Immune System in Health and in Disease, Immunodiagnostics, Innovation in Immunology Diagnostics, Intellectual Property, Innovations, Commercialization, Investment in technological breakthrough, Interviews with Scientific Leaders, Medical and Population Genetics, Molecular Genetics & Pharmaceutical, Personalized and Precision Medicine & Genomic Research, Pharmaceutical Analytics, Pharmaceutical R&D Investment, Pharmacogenomics, Pharmacologic toxicities, Population Health Management, Genetics & Pharmaceutical, Proteomics, Regulated Clinical Trials: Design, Methods, Components and IRB related issues, Scientist: Career considerations, Signaling, Technology Transfer: Biotech and Pharmaceutical, Translational Science on May 27, 2014| Leave a Comment »

Immunity and Host Defense – A Bibliography of Research @Technion

Reporter: Aviva Lev-Ari, PhD, RN

Article ID #138: Immunity and Host Defense – A Bibliography of Research @Technion. Published on 5/27/2014

WordCloud Image Produced by Adam Tubman

 

 

 

Antigen-Dependent Integration of Opposing Proximal TCR-Signaling Cascades Determines the Functional Fate of T Lymphocytes 2014 Shai Shen-Orr, PhD Authors : Wolchinsky R, Hod-Marco M, Oved K, Shen-Orr SS, Bendall SC, Nolan GP, Reiter Y. J Immunol. 2014 Mar 1;192(5):2109-19.

Identification of functionally important conserved trans-membrane residues of bacterial P(IB) -type ATPases 2013 Oded Lewinson, PhD Authors : Zhitnitsky D, Lewinson O. Mol Microbiol. 2013 Dec 19. doi: 10.1111/mmi.12495. [Epub ahead of print] PubMed PMID: 24350798.

Variability in the immune system: of vaccine responses and immune states 2013 Shai Shen-Orr, PhD Authors : Shen-Orr SS, Furman D. Curr Opin Immunol. 2013 Aug;25(4):542-7.

Computational deconvolution: extracting cell type-specific information from heterogeneous samples. 2013 Shai Shen-Orr, PhD Authors : Shen-Orr SS, Gaujoux R. Curr Opin Immunol. 2013 Oct 19. [Epub ahead of print] PubMed PMID: 24148234.

Challenges and promise for the development of human immune monitoring. 2013 Shai Shen-Orr, PhD Authors : Shen-Orr S. Rambam Maimonides Med J. 2012 Oct 31;3(4):e0023.

Homeostatic regulation of aging and rejuvenation in the B lineage cells 2013 Doron Melamed, PhD Authors : Melamed D. Crit Rev Immunol. 2013;33(1):41-56.

Variability in the immune system: of vaccine responses and immune states 2013 Shai Shen-Orr, PhD Authors : Shen-Orr S, Furman D. Curr Opin Immunol. 2013 Aug 13. doi:pii: S0952-7915(13)00113-1.

A single intact ATPase site of the ABC transporter BtuCD drives 5% transport activity yet supports full in-vivo vitamin B12 utilization. 2013 Oded Lewinson, PhD Authors : Tal N, Ovcharenko E, Lewinson O. Proc Natl Acad Sci U S A. (March 19 Epub ahead of print)

Apoptosis and other immune biomarkers predict influenza vaccine responsiveness. 2013 Shai Shen-Orr, PhD Authors : Furman D, Jojic V, Kidd B, Shen-Orr S, Price J, Jarrell J, Tse T, Huang H, Lund P, Maecker HT, Utz PJ, Dekker CL, Koller D, Davis MM. Molecular Systems Biology. 9, 659

The dual roles of inflammatory cytokines and chemokines in the regulation of autoimmune diseases and their clinical implications. 2013 Nathan Karin, PhD Authors : Shachar, I., and N. Karin. J Leukoc Biol 93:51-61.

Two molybdate/tungstate ABC transporters that interact very differently with their substrate binding proteins. 2013 Oded Lewinson, PhD Authors : Vigonsky, Ovcharenko E, Lewinson O. Proc Natl Acad Sci U S A. (March 19 Epub ahead of print)

Dissecting the Autocrine and Paracrine Roles of the CCR2-CCL2 Axis in Tumor Survival and Angiogenesis. 2012 Nathan Karin, PhD Authors : Izhak, L., G. Wildbaum, S. Jung, A. Stein, Y. Shaked, and N. Karin. PloS one 7:e28305

Dose-related effects of hyperoxia on the lung inflammatory response in septic rats 2012 Nitza Lahat, PhD Authors : Waisman D, Brod V, Rahat MA, Amit-Cohen BC, Lahat N, Rimar D, Menn-Josephy H, David M, Lavon O, Cavari Y, Bitterman H. Shock. 2012 Jan;37(1):95-102.

Robust and sensitive analysis of xMap bead arrays using SAxCyB. 2012 Shai Shen-Orr, PhD Authors : Won JH, Goldberger O, Shen-Orr SS, David MM, Olshen RA. Proc Natl Acad Sci U S A. 109, 2848-53.

The Entamoeba histolytica methylated LINE-binding protein EhMLBP provides protection against heat shock 2012 Serge Ankri, PhD Authors : Katz S, Kushnir O, Tovy A, Siman Tov R, Ankri S. Cell Microbiol. 2012 Jan;14(1):58-70

Hypoxia increases membranal and secreted HLA-DR in endothelial cells, rendering them T-cell activators. 2011 Nitza Lahat, PhD Authors : Lahat N, Bitterman H, Weiss-Cerem L, Rahat MA. Transpl Int. 2011 Oct;24(10):1018-26.

The Entamoeba histolytica methylated LINE-binding protein EhMLBP provides protection against heat shock. 2011 Serge Ankri, PhD Authors : Katz S, Kushnir O, Tovy A, Siman Tov R, Ankri S. Cell Microbiol. 2011 Sep 8. [Epub ahead of print]

Dose-Related Effects of Hyperoxia on the Lung Inflammatory Response in Septic Rats. Shoc 2011 Nitza Lahat, PhD Authors : Waisman D, Brod V, Rahat MA, Amit-Cohen BC, Lahat N, Rimar D, Menn-Josephy H, David M, Lavon O, Cavari Y, Bitterman H. 2011 Sep 3. [Epub ahead of print]

Glucose starvation boosts Entamoeba histolytica virulence. 2011 Serge Ankri, PhD Authors : Tovy A, Hertz R, Siman-Tov R, Syan S, Faust D, Guillen N, Ankri S. PLoS Negl Trop Dis. 2011 Aug;5(8):e1247.

The binding activity of Mel-18 at the Il17a promoter is regulated by the integrated signals of the TCR and polarizing cytokines. 2011 Eur J Immunol. 2011 Aug;41(8):2424-35.

phosphorylation of SLP-76 at tyrosine 173 is required for activation of T and mast cells. 2011 Deborah Yablonski, PhD Authors : Sela M, Bogin Y, Beach D, Oellerich T, Lehne J, Smith-Garvin JE, Okumura M, Starosvetsky E, Kosoff R, Libman E, Koretzky G, Kambayashi T, Urlaub H, Wienands J, Chernoff J, Yablonski D. Sequential EMBO J. 2011 Jul 1;30(15):3160-72.

The binding activity of Mel-18 at the Il17a promoter is regulated by the integrated signals of the TCR and polarizing cytokines. 2011 Orly Avni, PhD Authors : Hod-Dvorai R, Jacob E, Boyko Y, Avni O. Eur J Immunol. 2011 Jun 15. [Epub ahead of print]

MMP expression in leaking filtering blebs and tears after glaucoma filtering surgery. 2011 Nitza Lahat, PhD Authors : Mathalone N, Marmor S, Rahat MA, Lahat N, Oron Y, Geyer O. Graefes Arch Clin Exp Ophthalmol. 2011 Mar 31. [Epub ahead of print]

B cell depletion reactivates B lymphopoiesis in the BM and rejuvenates the B lineage in aging. 2011 Doron Melamed, PhD Authors : Keren Z, Naor S, Nussbaum S Golan K, Itkin T, Sasaki Y, Schmidt-Supprian M, Lapidot T, Melamed D. Blood 117, 3104 – 3112.

Chronic B cell deficiency from birth prevents age-related alterations in the B lineage J. 2011 Doron Melamed, PhD Authors : Keren Z, Averbuch D, Shahaf G, Zisman-Rozen S, Golan K, Itkin T, Lapidot T, Mehr R, Melamed D. Immunol 187, 2140 – 2147.

Epigenetics in the unicellular parasite Entamoeba histolytica. 2010 Serge Ankri, PhD Authors : Tovy A, Ankri S. Future Microbiol. 2010 Dec;5:1875-84.

The MAPK/ERK and PI3K pathways additively coordinate the transcription of recombination-activating genes in B lineage cells 2010 Orly Avni, PhD Authors : Novak R, Jacob E, Haimovich J, Avni O, Melamed D. J Immunol. 2010 Sep 15;185(6):3239-47

A fusion protein encoding the second extracellular domain of CCR5 arrests chemokine-induced cosignaling and effectively suppresses ongoing experimental autoimmune encephalomyelitis 2010 Nathan Karin, PhD Authors : Sapir Y, Vitenshtein A, Barsheshet Y, Zohar Y, Wildbaum G, Karin N. J Immunol. 2010 Aug 15;185(4):2589-99.

Antigen-specific CD25- Foxp3- IFN-gamma(high) CD4+ T cells restrain the development of experimental allergic encephalomyelitis by suppressing Th17 2010 Nathan Karin, PhD Authors : Wildbaum G, Zohar Y, Karin N. Am J Pathol. 2010 Jun; 176(6):2764-75.

Circulating interleukin-10: association with higher mortality in systolic heart failure patients with elevated tumor necrosis factor-alpha 2010 Nitza Lahat, PhD Authors : Amir O, Rogowski O, David M, Lahat N, Wolff R, Lewis BS. Isr Med Assoc J. 2010 Mar;12(3):158-62.

In vitro tRNA Methylation Assay with the Entamoeba histolytica DNA and tRNA Methyltransferase Dnmt2 (Ehmeth) Enzyme 2010 Serge Ankri, PhD Authors : Tovy A, Hofmann B, Helm M, Ankri S. J Vis Exp. 2010 Oct 19;(44). pii: 2390. doi: 10.3791/2390.

Circulating interleukin-10: association with higher mortality in systolic heart failure patients with elevated tumor necrosis factor-alpha 2010 Nitza Lahat, PhD Authors : Amir O, Rogowski O, David M, Lahat N, Wolff R, Lewis BS Isr Med Assoc J. 2010 Mar;12(3):158-62

A distinct mechanism for the ABC transporter BtuCD-BtuF revealed by the dynamics of complex formation. 2010 Oded Lewinson, PhD Authors : Lewinson O, Lee AT, Locher KP, Rees DC. Nat Struct Mol Biol. 17, 332-8.

Extracting Cell-Type-Specific Gene Expression Differences from Complex Tissues. 2010 Shai Shen-Orr, PhD Authors : Shen-Orr SS*, Tibshirani R*, Khatri P, Bodian DL, Staedtler F, Perry NM, Hastie T, Sarwal MM, Davis MM*, Butte AJ*. Nature Methods 7, 287-9.

The MAPK/ERK and PI(3)K Pathways Additively Coordinate the Transcription of Recombination-Activating Genes in B Lineage Cells. 2010 Doron Melamed, PhD Authors : Novak R, Jacob E, Haimovich J, Avni O, Melamed D. Immunol 185, 3239 – 3247.

Protein denitrosylation: enzymatic mechanisms and cellular functions 2009 Moran Benhar, PhD Authors : Benhar, M., Forrester, M.T., Stamler, J.S. Nat. Rev. Mol. Cell Biol. 10:721-32.

Psoriasis patients generate increased serum levels of autoantibodies to tumor necrosis factor-alpha and interferon-alpha 2009 Nathan Karin, PhD Authors : Bergman R, Ramon M, Wildbaum G, Avitan-Hersh E, Mayer E, Shemer A, Karin N. J Dermatol Sci. 2009 Oct 1. Epub

The role of macrophage-derived IL-1 in induction and maintenance of angiogenesis 2009 Nitza Lahat, PhD Authors : Carmi Y, Voronov E, Dotan S, Lahat N, Rahat MA, Fogel M, Huszar M, White MR, Dinarello CA, Apte RN. J Immunol. 2009 Oct 1;183(7):4705-14.

Insights into the mechanism of DNA recognition by the methylated LINE binding protein EhMLBP of Entamoeba histolytica 2009 Serge Ankri, PhD Authors : Lavi T, Siman-Tov R, Ankri S. Mol Biochem Parasitol. 2009 Aug;166(2):117-25. Epub 2009 Mar 20.

A novel recombinant fusion protein encoding a 20-amino acid residue of the third extracellular (E3) domain of CCR2 neutralizes the biological activity of CCL2 2009 Nathan Karin, PhD Authors : Izhak L, Wildbaum G, Zohar Y, Anunu R, Klapper L, Elkeles A, Seagal J, Yefenof E, Ayalon-Soffer M, Karin N J Immunol. 2009 Jul 1;183(1):732-9

Selective autoantibody production against CCL3‭ ‬is associated with human type 1‭ ‬diabetes mellitus and serves as a novel biomarker for its diagnosis 2009 Nathan Karin, PhD Authors : Shehadeh N‭, ‬Pollack S‭, ‬Wildbaum G‭, ‬Zohar Y‭, ‬Shafat I‭, ‬Makhoul R‭, ‬Daod E‭,‬ J Immunol‭. ‬2009‭ ‬Jun 15‭;‬182‭(‬12‭):‬8104-9

The effect of 100% oxygen on intestinal preservation and recovery following ischemia-reperfusion injury in rats 2009 Nitza Lahat, PhD Authors : Sukhotnik I, Brod V, Lurie M, Rahat MA, Shnizer S, Lahat N, Mogilner JG, Bitterman H. Crit Care Med. 2009 Mar;37(3):1054-61.

Transcriptional regulation of GATA3 in T helper cells by the integrated activities of transcription factors downstream of the interleukin-4 receptor and T cell receptor 2009 Orly Avni, PhD Authors : Scheinman EJ, Avni O. J Biol Chem. 2009 30;284(5):3037-48.

TOLL-like receptor ligands stimulate aberrant class switch recombination in early B cell precursors 2008 Doron Melamed, PhD Authors : Edry E, Azulay-Debby H, Melamed D. Int Immunol. 2008 Dec;20(12):1575-85. Epub 2008 Oct 29.

EhMLBP is an essential constituent of the Entamoeba histolytica epigenetic machinery and a potential drug target 2008 Serge Ankri, PhD Authors : Lavi T, Siman-Tov R, Ankri S. Mol Microbiol. 2008 Jul;69(1):55-66. Epub 2008 May 12

Hypoxia enhances lysosomal TNF-α degradation in mouse peritoneal macrophages 2008 Nitza Lahat, PhD Authors : Lahat, N., Rahat, M. A., Kinarty, A., Weiss-Cerem, L., Pinchevski, S., Bitterman, H. Am J Physiol Cell Physiol 295, C2-12.

What do unicellular organisms teach us about DNA methylation? 2008 Serge Ankri, PhD Authors : Harony H Trends Parasitol. 2008 May;24(5):205-9. Epub 2008 Apr 9. PMID: 18403268 [PubMed – in process]

Regulated protein denitrosylation by cytosolic and mitochondrial thioredoxins 2008 Moran Benhar, PhD Authors : Benhar, M., Forrester, M.T., Hess, D.T., Stamler, J.S. Science 320:1050-4

Trichostatin A regulates peroxiredoxin expression and virulence of the parasite Entamoeba histolytica. 2008 Serge Ankri, PhD Authors : Isakov E, Siman-Tov R, Weber C, Guillen N Mol Biochem Parasitol. 2008 Mar;158(1):82-94.

Progress and prospects of gene inactivation in Entamoeba histolytica. 2008 Serge Ankri, PhD Authors : Abed M Exp Parasitol. 2008 Feb;118(2):151-5

Class switch recombination: a friend and a foe. 2007 Doron Melamed, PhD Authors : Edry E. Clin Immunol. 2007 Jun;123(3):244-51.

Native and fragmented fibronectin oppositely modulate monocyte secretion of MMP-9 2007 Nitza Lahat, PhD Authors : Marom, B., Rahat, M. A., Lahat, N., Weiss-Cerem, L., Kinarty, A., Bitterman, H. J Leukoc Biol 81, 1466-1476.

SLP-76 mediates and maintains activation of the Tec family kinase ITK via the T cell antigen receptor-induced association between SLP-76 and ITK. 2007 Deborah Yablonski, PhD Authors : Bogin Y, Ainey C, Beach D Proc Natl Acad Sci U S A. 2007 Apr 17;104(16):6638-43.

Dual role of SLP-76 in mediating T cell receptor-induced activation of phospholipase C-gamma1. 2007 Deborah Yablonski, PhD Authors : Beach D, Gonen R, Bogin Y, Reischl IG J Biol Chem. 2007 Feb 2;282(5):2937-46. Epub 2006 Dec 4. Read the Article

B cell receptor editing in tolerance and autoimmunity. 2007 Doron Melamed, PhD Authors : Azulay-Debby H. Front Biosci. 2007 Jan 1;12:2136-47.

Genome-wide analysis of mRNA polysomal profiles with spotted DNA microarrays. 2007 Doron Melamed, PhD Authors : Arava Y. Methods Enzymol. 2007;431:177-201

Coadministration of plasmid DNA constructs encoding an encephalitogenic determinant and IL-10 elicits regulatory T cell-mediated protective immunity in the central nervous system. 2006 Nathan Karin, PhD Authors : Schif-Zuck S, Wildbaum G, Karin N. J Immunol. 2006 Dec 1;177(11):8241-7.

Sensing DNA methylation in the protozoan parasite Entamoeba histolytica. 2006 Serge Ankri, PhD Authors : Lavi T, Isakov E, Harony H, Fisher O, Siman-Tov R. Mol Microbiol. 2006 Dec;62(5):1373-86. Read the Article:

Modulation of matrix metalloproteinase-9 (MMP-9) secretion in B lymphopoiesis. 2006 Doron Melamed, PhD Authors : Melamed D, Messika O, Glass-Marmor L, Miller A. Int Immunol. 2006 Sep;18(9):1355-62.

A Pak- and Pix-dependent branch of the SDF-1alpha signalling pathway mediates T cell chemotaxis across restrictive barriers. 2006 Deborah Yablonski, PhD Authors : Volinsky N, Gantman A, Yablonski D. Biochem J. 2006 Jul 1;397(1):213-22. PMID: 16515536 [PubMed – in process] Read more

DNA methylation and targeting of LINE retrotransposons in Entamoeba histolytica and Entamoeba invadens. 2006 Serge Ankri, PhD Authors : Harony H, Bernes S, Siman-Tov R, Ankri S. Mol Biochem Parasitol. 2006 May;147(1):55-63. Epub 2006 Feb 23. PMID: 16530279 [PubMed � in process] Read more

Pleiotropic phenotype in Entamoeba histolytica overexpressing DNA methyltransferase (Ehmeth). 2006 Serge Ankri, PhD Authors : Fisher O, Siman-Tov R, Ankri S. Mol Biochem Parasitol. 2006 May;147(1):48-54. Epub 2006 Feb 9. PMID: 16497397 [PubMed � in process] Read more

Hypoxia reduces the output of matrix metalloproteinase-9 (MMP-9) in monocytes by inhibiting its secretion and elevating membranal association 2006 Nitza Lahat, PhD Authors : Rahat, M. A., Marom, B., Bitterman, H., Weiss-Cerem, L., Kinarty, A., Lahat, N. J Leukoc Biol 79, 706-718.

Antisense inhibition of Entamoeba histolytica cysteine proteases inhibits colonic mucus degradation 2006 Serge Ankri, PhD Authors : Moncada D, Keller K, Ankri S, Mirelman D, Chadee K. Gastroenterology. 2006 Mar;130(3):721-30. PMID: 16530514 [PubMed � indexed for MEDLINE] Read more

Beneficial autoimmunity participates in the regulation of rheumatoid arthritis. 2006 Nathan Karin, PhD Authors : Zohar Y, Wildbaum G, Karin N. Front Biosci. 2006 Jan 1;11:368-79. Review. PMID: 16146738 [PubMed – indexed for MEDLINE] Read more

The RNA polymerase II subunit Rpb4p mediates decay of a specific class of mRNAs. 2005 Doron Melamed, PhD Authors : Lotan R, Bar-On VG, Harel-Sharvit L, Duek L, Melamed D, Choder M. Genes Dev. 2005 Dec 15;19(24):3004-16. PMID: 16357218 [PubMed – indexed for MEDLINE] Read more

Single point mutations in the zinc finger motifs of the human immunodeficiency virus type 1 nucleocapsid alter RNA binding specificities of the gag protein and enhance packaging and infectivity. 2005 Doron Melamed, PhD Authors : Mark-Danieli M, Laham N, Kenan-Eichler M, Castiel A, Melamed D, Landau M, Bouvier NM, Evans MJ, Bacharach E. J Virol. 2005 Jun;79(12):7756-67. PMID: 15919928 [PubMed – indexed for MEDLINE] Read more

Molecular characterization of Entamoeba histolytica Rnase III and AGO2, two RNA interference hallmark proteins. 2005 Serge Ankri, PhD Authors : Abed M, Ankri S. Exp Parasitol. 2005 Jul;110(3):265-9. Epub 2005 Apr 7. PMID: 15955322 [PubMed � indexed for MEDLINE] Read more

Targeted overexpression of IL-18 binding protein at the central nervous system overrides flexibility in functional polarization of antigen-specific Th2 cells. 2005 Nathan Karin, PhD Authors : Schif-Zuck S, Westermann J, Netzer N, Zohar Y, Meiron M, Wildbaum G, Karin N. Immunol. 2005 Apr 1;174(7):4307-15. PMID: 15778395 [PubMed – indexed for MEDLINE] Read more

T cell receptor-induced activation of phospholipase C-gamma1 depends on a sequence-independent function of the P-I region of SLP-76. 2005 Deborah Yablonski, PhD Authors : Gonen R, Beach D, Ainey C, Yablonski D. J Biol Chem. 2005 Mar 4;280(9):8364-70. Epub 2004 Dec 28. PMID: 15623534 [PubMed – indexed for MEDLINE] Read more

Naive, effector, and memory T lymphocytes efficiently scan dendritic cells in vivo: contact frequency in T cell zones of secondary lymphoid organs does not depend on LFA-1 expression and facilitates 2005 Nathan Karin, PhD Authors : Westermann J, Bode U, Sahle A, Speck U, Karin N, Bell EB, Kalies K, Gebert A. J Immunol. 2005 Mar 1;174(5):2517-24. PMID: 15728457 [PubMed – indexed for MEDLINE] Read more

Antigen receptor signaling competence and the determination of B cell fate in B-lymphopoiesis. 2005 Doron Melamed, PhD Authors : Keren Z, Melamed D. Histol Histopathol. 2005 Jan;20(1):187-96. Review. PMID: 15578437 [PubMed – indexed for MEDLINE] Read more

CD19 regulates positive selection and maturation in B lymphopoiesis: lack of CD19 imposes developmental arrest of immature B cells and consequential stimulation of receptor editing. 2005 Doron Melamed, PhD Authors : Diamant E, Keren Z, Melamed D. Blood ;105:3247-3254.

Entamoeba histolytica DNA methyltransferase (Ehmeth) is a nuclear matrix protein that binds EhMRS2, a DNA that includes a scaffold/matrix attachment region (S/MAR). 2005 Serge Ankri, PhD Authors : Banerjee S, Fisher O, Lohia A, Ankri S. Mol Biochem Parasitol. 2005 Jan;139(1):91-7. PMID: 15610823 [PubMed � indexed for MEDLINE] Read more

Epigenetic and classical activation of Entamoeba histolytica heat shock protein 100 (EHsp100) expression. 2005 Serge Ankri, PhD Authors : Bernes S, Siman-Tov R, Ankri S. FEBS Lett;579:6395-6402.

T cell receptor-induced activation of phospholipase C-γ1 depends on a sequence-independent function of the P-I region of SLP-76. 2005 Deborah Yablonski, PhD Authors : Gonen R, Beach D, Ainey C, Yablonski D. J Biol Chem ;280:8364-8370.

Characterization of cytosine methylated regions and 5-cytosine DNA methyltransferase (Ehmeth) in the protozoan parasite Entamoeba histolytica. 2004 Serge Ankri, PhD Authors : Fisher O, Siman-Tov R, Ankri S. Nucleic Acids Res ;1:287-297.

Modification of ligandindependent B cell receptor tonic signals activates receptor editing in immature B lymphocytes. 2004 Doron Melamed, PhD Authors : Keren Z, Diamant E, Ostrovsky O, Bengal E, Melamed D. J Biol Chem ;279:13418-13424.

A failsafe mechanism for negative selection of isotype-switched B cell precursors is regulated by the Fas/FasL pathway 2003 Doron Melamed, PhD Authors : Seagal J, Edry E, Keren Z, Leider N, Benny O, Machluf M, Melamed D. J Exp Med ;198:1609-1619.

Beneficial autoimmunity to proinflammatory mediators restrains the consequences of self-destructive immunity. 2003 Nathan Karin, PhD Authors : Wildbaum G, Nahir MA, Karin N. Immunity;19:679-688.

T(H) cell differentiation is accompanied by dynamic changes in histone acetylation of cytokine genes. 2002 Orly Avni, PhD Authors : Avni O, Lee D, Macian F, Szabo SJ, Glimcher LH, Rao A. Nat Immunol ;3:643-651.

Tr1 cell-dependent active tolerance blunts the pathogenic effects of determinant spreading. 2002 Nathan Karin, PhD Authors : Wildbaum G, Netzer N, Karin N. J Clin Invest ;110:701-710.

A PAK1-PIX-PKL complex is activated by the T-cell receptor independent of Nck, Slp-76 and LAT. 2001 Deborah Yablonski, PhD Authors : Ku GM, Yablonski D, Manser E, Lim L, Weiss A. EMBO Journal ;20:457-465.

Identification of a phospholipase C-γ1 (PLC- γ1) SH3 domain-binding site in SLP-76 required for T-cell receptor-mediated activation of PLC-γ1 and NFAT 2001 Deborah Yablonski, PhD Authors : Yablonski D, Kadlecek T, Weiss A. Mol Cell Biol ;21:4208-4218.

C-C chemokineencoding DNA vaccines enhance breakdown of tolerance to their gene products and treat ongoing adjuvant arthritis. 2000 Nathan Karin, PhD Authors : Youssef S, Maor G, Wildbaum G, Grabie N, Gour-Lavie A, Karin N. J Clin Invest ;106:361-371.

Cell-type-restricted binding of the transcription factor NFAT to a distal IL-4 enhancer in vivo. 2000 Orly Avni, PhD Authors : Agarwal S, Avni O, Rao A. Immunity ;12:643-652.

T cell differentiation: a mechanistic view. 2000 Orly Avni, PhD Authors : Avni O, Rao A. Curr Opin Immunol; 12:654-659.

A systemic cytokine response defect stratifies older adults into distinct immune profiles. 1900 Shai Shen-Orr, PhD Authors : Shen-Orr SS*, Furman D*, Kidd BA, Morgan A, Lovelace P, Rosenberg-Hasson Y, Maecker H, Mackey S, Dekker C, Butte AJ, Davis MM. Submitted.

 

Share this:

• X
• LinkedIn
• Facebook
• Print
• Email

Like this:

Like Loading…

Read Full Post »

Heroes in Medical Research: Developing Models for Cancer Research

Posted in CANCER BIOLOGY & Innovations in Cancer Therapy, Genome Biology, Health Economics and Outcomes Research, Human Immune System in Health and in Disease, Scientist: Career considerations, Translational Research, tagged animal models of disease, Aviva Lev-Ari, Cancer - General, cancer models, Cell Biology, cloning, Conditions and Diseases, Developmental biology, DNA, gene expression, genetics, history of science, mouse model, National Institutes of Health, Proceedings of the National Academy of Sciences of the United States of America, research, scientific discovery on April 4, 2014| Leave a Comment »

Heroes in Medical Research: Developing Models for Cancer Research

Author, Curator: Stephen J. Williams, Ph.D.

 

The current rapid progress in cancer research would have never come about if not for the dedication of past researchers who had developed many of the scientific tools we use today. In this issue of Heroes in Medical Research I would like to give tribute to the researchers who had developed the some of the in-vivo and in-vitro models which are critical for cancer research.

 

The Animal Modelers in Cancer Research

Helen Dean King, Ph.D. (1869-1955)

Helen Dean King, Ph.D. from www.ExplorePAhistory.com; photo Courtesy of the Wistar Institute Archive Collection, Philadelphia, PA

 

 

The work of Dr. Helen Dean King on rat inbreeding led to development of strains of laboratory animals. Dr. King taught at Bryn Mawr College, then worked at University of Pennsylvania and the Wistar Institute under famed geneticist Thomas Hunt Morgan, researching if inbreeding would produce harmful genetic traits.   At University of Pennsylvania she examined environmental and genetic factors on gender determination.

 

 

 

 

Important papers include [1-6]as well as the following contributions:

“Studies in Inbreeding”, “Life Processes in Gray Norway Rats During Fourteen Years in Captivity”, doctoral thesis on embryologic development in toads (1899)

 

Milestones include:

 

1909    started albino rat breeding and bred 20 female and male from same litter (King colony) to 25

successive generations (inbreeding did not cause harmful traits)

 

1919     started to domesticate the wild Norwegian rats that ran thru Philadelphia (six pairs Norway rats

thru 28 generations)

A good reference for definitions of rat inbreeding versus line generation including a history of Dr. King’s work can be found at the site: Munificent Mischief Rattery and a brief history here.[7] In addition, Dr. King had investigated using rat strains as a possible recipient for tumor cells. The work was an important advent to the use of immunodeficient models for cancer research.

 

As shown below Philadelphia became a hotbed for research into embryology, development, genetics, and animal model development.

 

Beatrice Mintz, Ph.D.

(Beatrice Minz, Ph.D.; photo credit Fox Chase Cancer Center, www.pubweb.fccc.edu)

Dr. Mintz, an embryologist and cancer researcher from Fox Chase Cancer Center in Philadelphia, PA, contributed some of the most seminal discoveries leading to our current understanding of genetics, embryo development, cellular differentiation, and oncogenesis, especially melanoma, while pioneering techniques which allowed the development of genetically modified mice.

If you get the privilege of hearing her talk, take advantage of it. Dr. Mintz is one of those brilliant scientists who have the ability to look at a clinical problem from the viewpoint of a basic biological question and, at the same time, has the ability to approach the well-thought out questions with equally well thought out experimental design. For example, Dr. Mintz asked if a cell’s developmental fate was affected by location in the embryo. This led to her work by showing teratocarcinoma tumor cells in the developing embryo could revert to a more normal phenotype, essentially proving two important concepts in development and tumor biology:

1. The existence of pluripotent stem cells
2. That tumor cells are affected by their environment (which led to future concepts of the importance of tumor microenvironment on tumor growth

Other seminal discoveries included:

• Development of the first mouse chimeras using novel cell fusion techniques
• With Rudolf Jaenisch in 1974, showed integration of viral DNA from SV40, could be integrated into the DNA of developing mice and persist into adulthood somatic cells, the first transgenesis in mice which led ultimately to:
• Development of the first genetically modified mouse model of human melanoma in 1993

Her current work, seen on the faculty webpage here, is developing mice with predisposition to melanoma to uncover risk factors associated with the early development of melanoma.

In keeping with the Philadelphia tradition another major mouse model which became seminal to cancer drug discovery was co-developed in the same city, same institute and described in the next section.

It is interesting to note that the first cloning of an animal, a frog, had taken place at the Institute for Cancer Research, later becoming Fox Chase Cancer Center, which was performed by Drs. Robert Briggs and Thomas J. King and reported in the 152 PNAS paper Transplantation of Living Nuclei From Blastula Cells into Enucleated Frogs’ Eggs.[8]

 

 The Immunodeficient Animal as a Model System for Cancer Research – Dr. Mel Bosma, Ph.D.

 

Melvin J. Bosma, Ph.D.; photo credit Fox Chase Cancer Center

In the summer of 1980 at Fox Chase Cancer Center, Dr. Melvin J. Bosma and his co-researcher wife Gayle discovered mice with deficiencies in common circulating antibodies and since, these mice were littermates, realized they had found a genetic defect which rendered the mice immunodeficient (upon further investigation these mice were unable to produce mature B and T cells). These mice were the first scid (severe combined immunodeficiency) colony. The scid phenotype was later found to be a result of a spontaneous mutation in the enzyme Prkdc {protein kinase, DNA activated, catalytic polypeptide} involved in DNA repair, and ultimately led to a defect in V(D)J recombination of immunoglobulins.

The emergence of this scid mouse was not only crucial for AIDS research but was another turning point in cancer research , as researchers now had a robust in-vivo recipient for human tumor cells. The orthotopic xenograft of human tumor cells now allowed for studies on genetic and microenvironmental factors affecting tumorigenicity, as well as providing a model for chemotherapeutic drug development (see Suggitt for review and references)[9]. A discussion of the pros and cons of the xenograft system for cancer drug discovery would be too voluminous for this post and would warrant a full review by itself. But before the advent of such scid mouse systems researchers relied on spontaneous and syngeneic mouse tumor models such as the B16 mouse melanoma and Lewis lung tumor model.

Other scid systems have been developed such as in the dog, horse, and pig. Please see the following post on this site The SCID Pig: How Pigs are becoming a Great Alternate Model for Cancer Research. The athymic (nude) mouse (nu/nu) also is a popular immunodeficient mouse model used for cancer research

Two other in-vivo tumor models: Patient Derived Xenografts (PDX) and Genetically Engineered Mouse models (GEM) deserve their own separate discussion however the success of these new models can be attributed to the hard work of the aforementioned investigators. Therefore I will post separately and curate PDX and GEM models of cancer and highlight some new models which are having great impact on cancer drug development.

 

References

1.         Loeb L, King HD: Transplantation and Individuality Differential in Strains of Inbred Rats. The American journal of pathology 1927, 3(2):143-167.

2.         Lewis MR, Aptekman PM, King HD: Retarding action of adrenal gland on growth of sarcoma grafts in rats. J Immunol 1949, 61(4):315-319.

3.         Aptekman PM, Lewis MR, King HD: Tumor-immunity induced in rats by subcutaneous injection of tumor extract. J Immunol 1949, 63(4):435-440.

4.         Lewis MR, Aptekman PM, King HD: Inactivation of malignant tissue in tumor-immune rats. J Immunol 1949, 61(4):321-326.

5.         Lewis MR, King HD, et al.: Further studies on oncolysis and tumor immunity in rats. J Immunol 1948, 60(4):517-528.

6.         Aptekman PM, Lewis MR, King HD: A method of producing in inbred albino rats a high percentage of immunity from tumors native in their strain. J Immunol 1946, 52:77-86.

7.         Ogilvie MB: Inbreeding, eugenics, and Helen Dean King (1869-1955). Journal of the history of biology 2007, 40(3):467-507.

8.         Briggs R, King TJ: Transplantation of Living Nuclei From Blastula Cells into Enucleated Frogs’ Eggs. Proceedings of the National Academy of Sciences of the United States of America 1952, 38(5):455-463.

9.         Suggitt M, Bibby MC: 50 years of preclinical anticancer drug screening: empirical to target-driven approaches. Clinical cancer research : an official journal of the American Association for Cancer Research 2005, 11(3):971-981.

 

Other posts on this site about Cancer, Animal Models of Disease, and other articles in this series include:

The SCID Pig: How Pigs are becoming a Great Alternate Model for Cancer Research

A Synthesis of the Beauty and Complexity of How We View Cancer

Guidelines for the welfare and use of animals in cancer research

Importance of Funding Replication Studies: NIH on Credibility of Basic Biomedical Studies

FDA Guidelines For Developmental and Reproductive Toxicology (DART) Studies for Small Molecules

Report on the Fall Mid-Atlantic Society of Toxicology Meeting “Reproductive Toxicology of Biologics: Challenges and Considerations:

What`s new in pancreatic cancer research and treatment?

Heroes in Medical Research: Dr. Carmine Paul Bianchi Pharmacologist, Leader, and Mentor

Heroes in Medical Research: Dr. Robert Ting, Ph.D. and Retrovirus in AIDS and Cancer

Heroes in Medical Research: Barnett Rosenberg and the Discovery of Cisplatin

Richard Lifton, MD, PhD of Yale University and Howard Hughes Medical Institute: Recipient of 2014 Breakthrough Prizes Awarded in Life Sciences for the Discovery of Genes and Biochemical Mechanisms that cause Hypertension

Reuben Shaw, Ph.D., a geneticist and researcher at the Salk Institute: Metabolism Influences Cancer

 

Share this:

• X
• LinkedIn
• Facebook
• Print
• Email

Like this:

Like Loading…

Read Full Post »

Human Longevity Inc (HLI) – $70M in Financing of Venter’s New Integrative Omics and Clinical Bioinformatics

Posted in Biological Networks, Gene Regulation and Evolution, Biomarkers & Medical Diagnostics, Biomedical Measurement Science, Cardiovascular Pharmacogenomics, Chemical Genetics, Competition in regenerative stem cell science, Computational Biology/Systems and Bioinformatics, Curation, Genome Biology, Genomic Testing: Methodology for Diagnosis, Intellectual Property, Innovations, Commercialization, Investment in technological breakthrough, International Global Work in Pharmaceutical, Interviews with Scientific Leaders, Personalized and Precision Medicine & Genomic Research, Pharmaceutical Analytics, Pharmaceutical R&D Investment, Pharmacogenomics, Population Health Management, Genetics & Pharmaceutical, Proteomics, Regenerative Biology and Medicine, Reproductive Andrology, Embryology, Genomic Endocrinology, Preimplantation Genetic Diagnosis and Reproductive Genomics, Scientist: Career considerations, Statistical Methods for Research Evaluation, Stem Cells for Regenerative Medicine, Technology Transfer: Biotech and Pharmaceutical, Translational Effectiveness, Translational Research, Translational Science on March 5, 2014| Leave a Comment »

Human Longevity Inc (HLI) – $70M in Financing of Venter’s New Integrative Omics and Clinical Bioinformatics

Reporter: Aviva Lev-Ari, PhD, RN

Article ID #121: Human Longevity Inc (HLI) – $70M in Financing of Venter’s New Integrative Omics and Clinical Bioinformatics. Published on 3/5/14

WordCloud Image Produced by Adam Tubman

Venter’s New Integrative Omics and Clinical Data Analysis Firm Lands $70M in Financing

March 04, 2014

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – J. Craig Venter today unveiled a new company called Human Longevity Inc. that will combine human genome, microbiome, and metabolome data coupled with clinical information to fuel development of new diagnostics, therapeutics, and stem cell treatments for diseases related to aging.

In a media briefing today, Venter said the company will “change the way medicine is practiced,” and will spearhead “a shift to a more preventive, genomic-based medicine model” that can lead to longer, healthier lives and lower healthcare costs.

Using $70 million in Series A financing, HLI initially plans to conduct genome, microbiome, and tumor sequencing on patients from the University of California, San Diego Moores Cancer Center and use their clinical phenotype and metabolomics data to create a massive database, Venter explained in a media briefing. HLI said the financing came from a small group of private investors. Though it didn’t disclose the names of those investors, The New York Times reported today that Illumina was among the backers.

Venter said the initial financing should keep the company going for about 18 months. HLI is building a long-term facility in San Diego that will be completed in about a year, Venter said, and it is currently in temporary facilities.

The firm plans to license data and knowledge to pharmaceutical and biotechnology firms and universities for their own research programs, while developing new therapeutics and diagnostics and providing sequencing services.

The company has already bought two Illumina HiSeq X Ten Sequencing Systems, and has inked an option to buy three more. It plans to sequence up to 40,000 human genomes per year initially and ramp up to 100,000 per year. HLI said it will conduct the first clinical project to include germ line, human genome, and tumor genome sequencing, along with a range of other types of information from each patient.

As part of its efforts, HLI has struck an agreement with Metabolon, under which the NC-based firm will provide biochemical profiling of the genomic samples that HLI collects.

Venter is co-founder, executive chairman and CEO of HLI, which also has agreed to a research services collaboration with the J. Craig Venter Institute, of which he is founder and CEO. That alliance will cover proteomics, infectious disease diagnostics, and the human microbiome.

The company said that it will tackle cancer first. Every patient at the UCSD Moores Cancer Center will have the opportunity to have their genome, microbiome, and tumors sequenced and analyzed as part of their treatment, said Venter. Other diseases of interest include diabetes, obesity, heart and liver diseases, and dementia.

Venter noted that 13 years ago it cost around $100 million and took nine months to sequence his genome, but now that cost has dropped to around $1,000 per genome.

“We are scaling up to do tens of thousands of genomes in the same time frame that it took to do one,” he said.

Through its agreement with HLI, Metabolon will characterize 2,400 chemicals in the bloodstream of 10,000 of the initial patients.

Venter said HLI plans to try to layer “the chemical data with the microbiome data, the human genome data, and most importantly the human phenotype data. We will be importing clinical records of every individual we are sequencing, so this will be one of the largest data studies in the history of science and medicine.”

“Hopefully,” Venter said, within 10 years HLI will “have data from half a million to a million human genomes, and the phenotype data, clinical data, and outcome data associated with that.”

“I view this as just the beginning, a starting point of this new field that some of us have been waiting for for a very long time, following on the first human genome 13 years ago,” he said.

Among Venter’s ventures is Synthetic Genomics, a genomics and synthetic biology firm of which he is a co-founder, chairman, CEO, and co-CSO. Though HLI didn’t say specifically that it would collaborate with Synthetic Genomics, according to a FAQ sheet on its website, it plans to use “synthetic biology advances to repair and repopulate a patient’s depleted and degraded stem cell population, returning those cells to a more healthy and youthful state.”

In addition to Venter, HLI’s two other co-founders are Peter Diamandis, chairman and CEO of the X Prize Foundation and co-founder and executive chairman of Singularity University, and stem cell biology researcher and entrepreneur Robert Hariri, who also will serve as company vice chairman.

SOURCE

http://www.genomeweb.com//node/1357581?utm_source=SilverpopMailing&utm_medium=email&utm_campaign=Venter’s%20New%20Firm;%20White%20House’s%20NIH%20Budget%20Proposal;%20CDx%20Licensing%20Deal;%20$3M%20Gift%20for%20Autism;%20More%20-%2003/04/2014%2004:15:00%20PM

Other articles published on this Open Access Online Scientific Journal include the following:

J Craig Venter wants to digitize DNA and transmit the signal to teleport organisms

Aviva Lev-Ari, PhD, RN

http://pharmaceuticalintelligence.com/2013/11/01/j-craig-venter-wants-to-digitize-dna-and-transmit-the-signal-to-teleport-organisms/

Life Sciences Circle Event: Next omics – Personalized Medicine beyond Genomics, December 11, 2013 5:30-8:30PM, The Broad Institute, Cambridge

Aviva Lev-Ari, PhD, RN

http://pharmaceuticalintelligence.com/2013/11/18/life-sciences-circle-event-next-omics-personalized-medicine-beyond-genomics-december-11-2013-530-830pm-the-broad-institute-cambridge/

2013 Genomics: The Era Beyond the Sequencing of the Human Genome: Francis Collins, Craig Venter, Eric Lander, et al.

Aviva Lev-Ari, PhD, RN

http://pharmaceuticalintelligence.com/2013/02/11/2013-genomics-the-era-beyond-the-sequencing-human-genome-francis-collins-craig-venter-eric-lander-et-al/

Synthetic Biology: On Advanced Genome Interpretation for Gene Variants and Pathways: What is the Genetic Base of Atherosclerosis and Loss of Arterial Elasticity with Aging

Aviva Lev-Ari, PhD, RN

http://pharmaceuticalintelligence.com/2013/05/17/synthetic-biology-on-advanced-genome-interpretation-for-gene-variants-and-pathways-what-is-the-genetic-base-of-atherosclerosis-and-loss-of-arterial-elasticity-with-aging/

Scientific Innovation: as Influenced by Academia, Publishing Requirements and the Academic Publishing Industry

Aviva Lev-Ari, PhD, RN

http://pharmaceuticalintelligence.com/2014/03/05/scientific-innovation-as-influenced-by-academia-publishing-requirements-and-the-academic-publishing-industry/

Fourth Annual QPrize Competition to Fund the World’s Next Groundbreaking Startups by Qualcomm Ventures

Aviva Lev-Ari, PhD, RN

http://pharmaceuticalintelligence.com/2014/02/09/fourth-annual-qprize-competition-to-fund-the-worlds-next-groundbreaking-startups-by-qualcomm-ventures/

Cancer Genomics – Leading the Way by Cancer Genomics Program at UC Santa Cruz

Aviva Lev-Ari, PhD, RN

http://pharmaceuticalintelligence.com/2012/10/29/cancer-genomics-leading-the-way-by-cancer-genomics-program-at-uc-santa-cruz/

Research Paradigm Shift in Human Genomics – Predictive Biomarkers and Personalized Medicine

Aviva Lev-Ari, PhD, RN

http://pharmaceuticalintelligence.com/2013/01/13/paradigm-shift-in-human-genomics-predictive-biomarkers-and-personalized-medicine-part-1/

LEADERS in the Competitive Space of Genome Sequencing of Genetic Mutations for Therapeutic Drug Selection in Cancer Personalized Treatment

Aviva Lev-Ari, PhD, RN

http://pharmaceuticalintelligence.com/2013/01/13/leaders-in-genome-sequencing-of-genetic-mutations-for-therapeutic-drug-selection-in-cancer-personalized-treatment-part-2/

Personalized Medicine: An Institute Profile – Coriell Institute for Medical Research

Aviva Lev-Ari, PhD, RN

http://pharmaceuticalintelligence.com/2013/01/13/personalized-medicine-an-institute-profile-coriell-institute-for-medical-research-part-3/

The Consumer Market for Personal DNA Sequencing

Aviva Lev-Ari, PhD, RN

http://pharmaceuticalintelligence.com/2013/01/13/consumer-market-for-personal-dna-sequencing-part-4/

Share this:

• X
• LinkedIn
• Facebook
• Print
• Email

Like this:

Like Loading…

Read Full Post »

2014 Breakthrough Prizes Awarded in Fundamental Physics and Life Sciences for a Total of $21 Million – MIT’s Robert Langer gets $3 Million

Posted in Scientist: Career considerations on March 3, 2014| Leave a Comment »

2014 Breakthrough Prizes Awarded in Fundamental Physics and Life Sciences for a Total of $21 Million – MIT’s Robert Langer gets $3 Million

Curator: Aviva Lev-Ari, PhD, RN

2014 Breakthrough Prizes Awarded in Fundamental Physics and Life Sciences for a Total of $21 Million

Mark Zuckerberg and Yuri Milner announced new $3 million Breakthrough Prize in Mathematics.

PR Newswire

SAN FRANCISCO, Dec. 13, 2013

SAN FRANCISCO, Dec. 13, 2013 /PRNewswire/ — The names of the 2014 Breakthrough Prize winners in Fundamental Physics and Life Sciences were unveiled at an exclusive ceremony at the NASA Ames Research Center, Mountain View, CA. At a total awarded amount of $21 million, sponsored by Sergey Brin & Anne Wojcicki, Jack Ma & Cathy Zhang, Yuri & Julia Milner and Mark Zuckerberg & Priscilla Chan, the prizes aim to celebrate scientists and generate excitement about the pursuit of science as a career.

The Breakthrough Prize in Fundamental Physics recognizes transformative achievements in the field of fundamental physics, with a special focus on recent developments. The 2014 winners are:

• Michael B. Green, University of Cambridge, and John H. Schwarz, California Institute of Technology,for opening new perspectives on quantum gravity and the unification of forces.

The Breakthrough Prize in Life Sciences recognizes excellence in research aimed at curing intractable diseases and extending human life. The 2014 recipients are:

• James Allison, MD Anderson Cancer Center for the discovery of T cell checkpoint blockade as effective cancer therapy.
• Mahlon DeLong, Emory University for defining the interlocking circuits in the brain that malfunction in Parkinson’s disease. This scientific foundation underlies the circuit-based treatment of Parkinson’s disease by deep brain stimulation.
• Michael Hall, University of Basel for the discovery of Target of Rapamycin (TOR) and its role in cell growth control.
• Robert Langer, David H. Koch Institute Professor at the Massachusetts Institute of Technology for discoveries leading to the development of controlled drug-release systems and new biomaterials.
• Richard Lifton, Yale University; Howard Hughes Medical Institute for the discovery of genes and biochemical mechanisms that cause hypertension.
• Alexander Varshavsky, California Institute of Technology for discovering critical molecular determinants and biological functions of intracellular protein degradation.

“Scientists should be celebrated as heroes, and we are honored to be part of today’s celebration of the newest winners of the Breakthrough Prize in Life Sciences and the Fundamental Physics Prize,” said Anne Wojcicki and Sergey Brin.

The prize ceremony was hosted by actor Kevin Spacey, and awards were presented by the Prize sponsors and by celebrities including Conan O’Brien, Glenn Close, Rob Lowe and Michael C. Hall. The event was organized in cooperation with Vanity Fair and produced and directed by Don Mischer, the producer and director of the Academy Awards, among other television and live events. Grammy-nominated singer Lana Del Ray performed live for the guests of the ceremony.

The event will be televised by the Science Channel, one of the Discovery networks; it will be broadcast at 9pm on January 27^th.

At the end of the ceremony, Mark Zuckerberg and Yuri Milner announced the launch of a new $3 million Breakthrough Prize in Mathematics. The details of the new prize will be announced at a later date.

“The Breakthrough Prize is our effort to put the spotlight on these amazing heroes. Their work in physics and genetics, cosmology, neurology and mathematics will change lives for generations and we are excited to celebrate them,” commented Mark Zuckerberg.

Yuri Milner said: “Einstein said, Pure mathematics is the poetry of logical ideas. It is in this spirit that Mark and myself are announcing a new Breakthrough Prize in Mathematics. The work that the Prize recognizes could be the foundation for genetic engineering, quantum computing or Artificial Intelligence; but above all, for human knowledge itself.”

This commitment to the pursuit and dissemination of knowledge is not limited to the Prize ceremony. On December 13, there will be two Breakthrough Prize Symposiums: at Stanford, on the Future of Fundamental Science; and at the University of California, San Francisco, on the Future of the Biological Sciences. Winners of the Breakthrough Prize from 2012, 2013 and 2014 will give lectures and take part in panel discussions before an invited audience.

Art Levinson, the chairman of the Breakthrough Prize in Life Sciences Foundation, said: “We are honored to recognize such an outstanding group of scientists as this year’s Breakthrough Prize Laureates. We are sure they will continue to push back the boundaries of knowledge in the years to come.”

About the Breakthrough Prizes

The Breakthrough Prize in Fundamental Physics and Life Sciences are founded by Sergey Brin & Anne Wojcicki, Jack Ma & Cathy Zhang, Yuri & Julia Milner and Mark Zuckerberg & Priscilla Chan. The prizes aim to celebrate scientists and generate excitement about the pursuit of science as a career. Breakthrough Prizes are funded by a grant from Sergey Brin and Anne Wojcicki’s foundation, The Brin Wojcicki Foundation; a grant from Mark Zuckerberg’s fund at the Silicon Valley Community Foundation; a grant from Jack Ma Foundation; and a grant from Milner Foundation. Laureates of all prizes are chosen by Selection Committees, which are comprised of prior recipients of the prizes.

The Selection Committee for the 2014 Breakthrough Prize in Fundamental Physics included:

• Nima Arkani-Hamed
• Lyn Evans
• Fabiola Gianotti
• Alan Guth
• Stephen Hawking
• Joseph Incandela
• Alexei Kitaev
• Maxim Kontsevich
• Andrei Linde
• Juan Maldacena
• Alexander Polyakov
• Nathan Seiberg
• Ashoke Sen
• Edward Witten

The Selection Committee for the 2014 Breakthrough Prize in Life Sciences included:

• Cornelia I. Bargmann
• David Botstein
• Lewis C. Cantley
• Hans Clevers
• Napoleone Ferrara
• Titia de Lange
• Eric S. Lander
• Charles L. Sawyers
• Bert Vogelstein
• Robert A. Weinberg
• Shinya Yamanaka

Additional information on the Breakthrough Prizes is available at:

www.breakthroughprizeinlifesciences.org

www.fundamentalphysicsprize.org

Media Contacts

Brunswick Group:
Oliver Phillips
breakthroughprize@brunswickgroup.com
+1 415 671 7676

Prize Foundations:
Leonid Solovyev
solovyev@fundamentalphysicsprize.org
+44 7590 976 334

SOURCE Brunswick Group

http://www.bizjournals.com/sanfrancisco/prnewswire/press_releases/California/2013/12/13/NY33121

Robert Langer, David H. Koch Institute Professor at the Massachusetts Institute of Technology for discoveries leading to the development of controlled drug-release systems and new biomaterials.

Robert S. Langer is the David H. Koch Institute Professor (there are 11 Institute Professors at MIT; being an Institute Professor is the highest honor that can be awarded to a faculty member).  Dr. Langer has written over 1,230 articles.  He also has 1,026 patents (512 issued) worldwide.  Dr. Langer’s patents have been licensed or sublicensed to over 250 pharmaceutical, chemical, biotechnology and medical device companies.  He is the most cited engineer in history. View CV (pdf)

He served as a member of the United States Food and Drug Administration’s SCIENCE Board, the FDA’s highest advisory board, from 1995 — 2002 and as its Chairman from 1999-2002.

Dr. Langer has received over 220 major awards.  He is one of 7 individuals to have received both the United States National Medal of Science (2006) and the United States National Medal of Technology and Innovation (2011).  He also received the 2002 Charles Stark Draper Prize, considered the equivalent of the Nobel Prize for engineers, the 2008 Millennium Prize, the world’s largest technology prize, the 2012 Priestley Medal, the highest award of the American Chemical Society, the 2013 Wolf Prize in Chemistry and the 2014 Breakthrough Prize in Life Sciences.  He is the also the only engineer to receive the Gairdner Foundation International Award; 82 recipients of this award have subsequently received a Nobel Prize.  Among numerous other awards Langer has received are the Dickson Prize for Science (2002), Heinz Award for Technology, Economy and Employment (2003), the Harvey Prize (2003), the John Fritz Award (2003) (given previously to inventors such as Thomas Edison and Orville Wright), the General Motors Kettering Prize for Cancer Research (2004), the Dan David Prize in Materials Science (2005), the Albany Medical Center Prize in Medicine and Biomedical Research (2005), the largest prize in the U.S. for medical research, induction into the National Inventors Hall of Fame (2006), the Max Planck Research Award (2008), the Prince of Asturias Award for Technical and Scientific Research (2008), the Warren Alpert Foundation Prize (2011) and the Terumo International Prize (2012).  In 1998, he received the Lemelson-MIT prize, the world’s largest prize for invention for being “one of history’s most prolific inventors in medicine.”  In 1989 Dr. Langer was elected to the Institute of Medicine of the National Academy of Sciences, and in 1992 he was elected to both the National Academy of Engineering and to the National Academy of Sciences, and in 2012 he was elected to the National Academy of Inventors.

Forbes Magazine (1999) and Bio World (1990) have named Dr. Langer as one of the 25 most important individuals in biotechnology in the world.  Discover Magazine (2002) named him as one of the 20 most important people in this area.  Forbes Magazine (2002) selected Dr. Langer as one of the 15 innovators world wide who will reinvent our future.  Time Magazine and CNN (2001) named Dr. Langer as one of the 100 most important people in America and one of the 18 top people in science or medicine in America (America’s Best).  Parade Magazine (2004) selected Dr. Langer as one of 6 “Heroes whose research may save your life.”  Dr. Langer has received honorary doctorates from Harvard University, the Mt. Sinai School of Medicine, Yale University, the ETH (Switzerland), the Technion (Israel), the Hebrew University of Jerusalem (Israel), the Universite Catholique de Louvain (Belgium), Rensselaer Polytechnic Institute, Willamette University, the University of Liverpool (England), Bates College, the University of Nottingham (England), Albany Medical College, Pennsylvania State University, Northwestern University, Uppsala University (Sweden), Tel Aviv University (Israel), Boston University, Ben Gurion University (Israel), Drexel University and the University of California – San Francisco Medal.  He received his Bachelor’s Degree from Cornell University in 1970 and his Sc.D. from the Massachusetts Institute of Technology in 1974, both in Chemical Engineering.

SOURCE

http://web.mit.edu/langerlab/langer.html

Langer Lab @MIT

Work is in progress in the following areas: Investigating the mechanism of release from polymeric delivery systems with concomitant microstructural analysis and mathematical modeling Studying applications of these systems including the development of effective long-term delivery systems for insulin, anti-cancer drugs, growth factors, gene therapy agents and vaccines Developing controlled release systems that can be magnetically, ultrasonically, or enzymatically triggered to increase release rates Synthesizing new biodegradable polymeric delivery systems which will ultimately be absorbed by the body Creating new approaches for delivering drugs such as proteins and genes across complex barriers in the body such as the blood-brain barrier, the intestine, the lung and the skin Researching new ways to create tissue and organs including creating new polymer systems for tissue engineering Stem cell research including controlling growth and differentiation Creating new biomaterials with shape memory or surface switching properties Angiogenesis inhibition

Publications of Langer Lab

http://web.mit.edu/langerlab/publications/index.html

SOURCE

http://web.mit.edu/langerlab/research/index.html

 

Related Sources:

Controlled Release Technology: Delivery Systems for Pharmaceuticals, Proteins, and Other Agents July 8-12, 2013 The ways in which chemicals or drugs are administered have gained increasing attention in the past two decades. Normally, a chemical is administered in a high dose at a given time only to have to repeat that dose several hours or days later. This is not economical and sometimes results in damaging side effects. As a consequence, increasing attention has been focused on methods of giving drugs continually for prolonged time periods and in a controlled fashion. The primary method of accomplishing this controlled release has been through incorporating the chemicals within polymers. This technology now spans many fields and includes pharmaceutical, food and agricultural applications, pesticides, cosmetics, and household products. In the pharmaceutical field, in addition to the importance of polymers, an understanding of the physiological barriers in the human body is also critical to developing appropriate controlled release systems. The skin, the gastrointestinal tract, the nose and the eye are of particular importance. Finally, recent advances in genetic engineering have spawned numerous new polypeptide agents. Approaches for delivering and stabilizing these molecules will be discussed. The lectures, in morning and afternoon sessions, will be presented by faculty members at MIT and other universities who are leaders in the topics to be covered. The lectures are intended to review the recent advances in the art and science of controlled release technology and to assess the prospects and directions of future developments. The program is designed for chemists, chemical engineers, pharmaceutical scientists, and technical managers with an interest in controlled release technology. Scientists in other fields such as food, agricultural, etc., may also benefit from this course. More on Controlled Release Technology Program >> More information about Short Programs: MIT Professional Education >> Teaching Faculty Dr. Robert S. Langer, Program Director, David H. Koch Institute Professor at MIT. Dr. Alexander Klibanov, Professor of Chemistry at MIT. Dr. Nicholas A. Peppas, Professor of Chemical Engineering, Biomedical Engineering and Pharmaceutics at the University of Texas at Austin. Dr. Frank Szoka, Professor for the College of Pharmacy at the University of California, San Francisco. SOURCE http://web.mit.edu/langerlab/summerprog.html   At MIT MIT Department of Chemical Engineering HST, Harvard-MIT Division of Health Sciences and Technology CPSE, Council on Primary and Secondary Education Program in Polymer Science & Technology BEH, Biological Engineering Division OSP, Office of Sponsored Programs UROP, Undergrad Research Opportunity Program BPEC, Biotechnology Process Engineering Center Langer Lab Research Collaborators  Prof. Jeffrey M. Karp Prof. Ali Khademhosseini Blog Site Engines of Innovation – New! Journals American Institute of Chemical Engineers AIChE Journal Chemical & Engineering News Chemical Engineering Progress Biomaterials Discover Journal of Controlled Release Nature New England Journal of Medicine PNAS Technology Review Science Scientific American SurFACTS in Biomaterials Time Web Resources ACS Chemistry.org American Academy of Arts and Sciences American Association for the Advancement of Science, “Triple A-S”, (AAAS) American Association of Pharmaceutical Scientists FDA Institute of Medicine National Academy of Engineering National Academy of Sciences NIH PubMed Society for Biomaterials  SOURCE http://web.mit.edu/langerlab/links.html

Share this:

• X
• LinkedIn
• Facebook
• Print
• Email

Like this:

Like Loading…

Read Full Post »

« Newer Posts - Older Posts »

• Follow Blog via Email

  Enter your email address to follow this blog and receive notifications of new posts by email.

  Email Address

  Follow

  Join 2,041 other subscribers

• Recent Posts

  • FDA Moves Forward With Its Guidance Framework for Rare Disease Trials: 2026 August 3, 2026
  • Artificial Intelligence TRANSFORMS Medicine, Biotech and Healthcare, How? August 3, 2026
  • In Memoriam: Nobel Laureate J. Michael Bishop for discovery of Retroviral Oncogenes July 31, 2026
  • Companies Actively Engaging Artificial Intellegence for Drug Design: 2026 July 31, 2026
  • AI-Native Drug Discovery Landscape 2026 – How LPBI Group Differentiates in the New Era of Foundation Models July 19, 2026
  • In Memoriam: In Remembrance of Cancer Researchers who passed in 2026 July 13, 2026
  • Urgent Request for Action on Proposed Rule Affecting Federal Funding Grant Review July 7, 2026
  • 2026 Tang Prize in Biopharmaceutical Science Awarded to Three Pioneers of Cellular Immunotherapy Revolutionizing Treatments for Blood Cancers and Solid Tumors July 5, 2026
  • Protected: KOL on Competitive Dynamics: LPBI Group’s Founder’s Radar Screens on AI-in-Health, Life Sciences & BioPharma June 15, 2026
  • Tumor Infiltrating Lymphocytes (TIL) as a first of kind FDA approved immunotherapy for cancer June 12, 2026

• Archives

  Archives Select Month August 2026  (2) July 2026  (6) June 2026  (4) May 2026  (1) January 2026  (10) December 2025  (8) November 2025  (8) October 2025  (12) September 2025  (2) July 2025  (4) June 2025  (8) May 2025  (4) April 2025  (2) March 2025  (1) February 2025  (2) January 2025  (3) December 2024  (1) November 2024  (5) October 2024  (7) September 2024  (7) August 2024  (1) June 2024  (1) May 2024  (2) April 2024  (2) January 2024  (1) November 2023  (1) October 2023  (3) September 2023  (3) August 2023  (2) July 2023  (2) June 2023  (7) May 2023  (4) April 2023  (2) March 2023  (5) February 2023  (2) January 2023  (3) December 2022  (2) October 2022  (6) September 2022  (2) August 2022  (1) July 2022  (3) June 2022  (3) May 2022  (8) April 2022  (10) March 2022  (7) February 2022  (7) January 2022  (3) December 2021  (3) November 2021  (4) October 2021  (11) September 2021  (5) August 2021  (8) July 2021  (21) June 2021  (8) May 2021  (10) April 2021  (8) March 2021  (15) February 2021  (17) January 2021  (20) December 2020  (10) November 2020  (12) October 2020  (26) September 2020  (17) August 2020  (22) July 2020  (27) June 2020  (33) May 2020  (26) April 2020  (42) March 2020  (22) February 2020  (11) January 2020  (7) December 2019  (20) November 2019  (13) October 2019  (11) September 2019  (3) August 2019  (8) July 2019  (25) June 2019  (47) May 2019  (40) April 2019  (27) March 2019  (29) February 2019  (17) January 2019  (50) December 2018  (14) November 2018  (17) October 2018  (18) September 2018  (17) August 2018  (8) July 2018  (20) June 2018  (22) May 2018  (17) April 2018  (12) March 2018  (20) February 2018  (26) January 2018  (16) December 2017  (6) November 2017  (20) October 2017  (13) September 2017  (16) August 2017  (16) July 2017  (19) June 2017  (20) May 2017  (32) April 2017  (21) March 2017  (10) February 2017  (24) January 2017  (21) December 2016  (43) November 2016  (8) October 2016  (40) September 2016  (67) August 2016  (59) July 2016  (75) June 2016  (37) May 2016  (95) April 2016  (152) March 2016  (175) February 2016  (196) January 2016  (139) December 2015  (90) November 2015  (287) October 2015  (237) September 2015  (115) August 2015  (96) July 2015  (63) June 2015  (44) May 2015  (53) April 2015  (76) March 2015  (95) February 2015  (83) January 2015  (75) December 2014  (75) November 2014  (88) October 2014  (135) September 2014  (117) August 2014  (88) July 2014  (88) June 2014  (109) May 2014  (60) April 2014  (85) March 2014  (58) February 2014  (72) January 2014  (107) December 2013  (104) November 2013  (136) October 2013  (62) September 2013  (32) August 2013  (46) July 2013  (74) June 2013  (110) May 2013  (112) April 2013  (86) March 2013  (92) February 2013  (63) January 2013  (63) December 2012  (46) November 2012  (71) October 2012  (84) September 2012  (82) August 2012  (122) July 2012  (59) June 2012  (34) May 2012  (46) April 2012  (2)

• Categories

  Categories Select Category 3D Printing for Medical Application  (239)    3D Plotting Scaffolds  (44)    BioInks  (34)       Biopolymer Blend Open Porous  (18)       Dental Applications  (10)    BioPrinting in Regenerative Medicine  (77)       Cell Level  (16)       MicroEngineering Cell-Tissue & Systems  (31)       Tissue Engineering  (37)    Cardiovascular and Vascular Systems  (30)       Artificial Vascular Structures  (9)       Cardiovascular Tissue  (8)    Drug Development using MultiOrgan Chip  (11)    Drug Development/Formulation using 3D Printing  (10)    MEMS  (16)       Bio-MEMS  (12)    Organ-on-a-Chip  (11)    Programmable Sensors (Carbon Nano Tubes)  (5) 3rd Party IP: Drug DIscovery  (1) 4D Printing and Meta Materials  (10) Academic Publishing  (223)    Key Opinion Leaders in eScientific Publishing – Interviews with  (8) Advanced Drug Manufacturing Technology  (96)    Antimalarial Preparation  (8)    Autologous Cell Therapy  (14)    Automated Cell Processing  (13) Allergy and Infectious Diseases  (12) Alzheimer’s Disease  (163)    Etiology  (77)    Medical Device Therapies for Altzheimer’s Disease  (15)    Pharmacotherapy and Cell Activity  (51) Anticancer Resistance  (31) Art Exhibits on the Human Condition  (1) Art Inspires Science  (4) Article Type  (2)    Authored  (1)    Curated  (2)    Scientific report  (1) Artificial Heart  (2) Artificial Intelligence – General  (239)    An executive’s guide to AI  (11)    Artificial Intelligence – Breakthroughs in Theories and Technologies  (119)    Artificial Intelligence Applications in Health Care  (130)       Artificial Intelligence in CANCER  (42)       Artificial Intelligence in Health Care – Tools & Innovations  (77)    Artificial Intelligence in Medicine – Application for Diagnosis  (72)       Artificial intelligence applications for cardiology  (33)          AI-assisted Cardiac MRI  (10)       Artificial Intelligence in Psychiatry  (7)       Deep Learning in Pathology  (19)    Artificial Intelligence in Medicine – Applications in Therapeutics  (71)    ChatGPT, GPT-4  (7)       ChatGPT at LPBI Group  (3)       ChatGPT in Academic Education  (3)    Machine Learning  (73)       Deep Learning  (26)       Natural Language Processing (NLP)  (45)    Machine learning in predicting type 2 diabetes  (6) Auditory and vision  (13) Autism Spectrum Disorders  (10) Autoimmune Inflammatory DIseases  (24)    Crohn’s disease  (5)    Tolerance-inducing Autoimmune Disease Therapeutics  (6)    Ulcerative Colitis  (3) Autophagosome  (4) Bacterial Resistance  (25) Behavior  (26) Behavioral Genetics  (21) Big Data  (88)    Intelligent Information Systems  (51) Bio Instrumentation in Experimental Life Sciences Research  (368)    Analytical Instruments Industry  (5)    Microfuidics  (8) Bio-Ethics  (16) BioBanking  (36) Biodegradable Drug-eluting Material  (8) Bioengineering & reverse engineering design  (43) BioIT: BioInformatics  (147) BioIT: BioInformatics, NGS, Clinical & Translational, Pharmaceutical R&D Informatics, Clinical Genomics, Cancer Informatics  (135)    Advanced Computing Platform  (32)       Blockchain Transactions System  (6)          Platform for Content Monetization embedded Content Promotion  (1)    Pancreatic adenocarcinoma classifier  (4)    Simulation Modeling in NGS  (5) Biological Engineering  (43) Biological Networks  (193) Biological Networks, Gene Regulation and Evolution  (479)    Virology  (10) Biomarkers & Medical Diagnostics  (571)    VOC – Volatile Organic Compounds as BioMarkers  (2) Biomedical Measurement Science  (173) BioSimilars  (112) BioTechnology – Venture Creation  (133)    Foundations for supporting Science and Education  (14)    Philanthropy to Academic Institution  (3) BioTechnology – Venture Creation, Venture Capital  (110)    Seeking Talent  (3) BiVAD  (1) Blindness  (6) Bone Disease and Musculoskeletal Disease  (82) Brain Basis of Emotion  (5) Business Career Consideration  (1) Ca2+ triggered activation  (61) Calcium  (21) Calcium Signaling  (71) Calmodulin Kinase and Contraction  (36) Cancer – General  (186) Cancer and Current Therapeutics  (412)    interventional oncology  (49)       Breast Cancer – impalpable breast lesions  (20)       Prostate Cancer: Monitoring vs Treatment  (9) CANCER BIOLOGY & Innovations in Cancer Therapy  (1,127)    Anaerobic Glycolysis  (51)    Cachexia  (18)    Cancer Genomics  (85)       Circulating Tumor Cells (CTC)  (27)          Liquid Biopsy Chip detects an array of metastatic cancer cell markers in blood  (17)             mRNA  (6)          MagSifter chip  (1)       KRAS Mutation  (9)       Li-fraumeni syndrome.  (4)       TP53 – Germline mutations  (9)    cancer metabolism  (28)    Funding Opportunities for Cancer Research  (13)    Genomic Expression  (150)    Glioblastoma  (7)    Hexokinase  (14)    Loss of function gene  (18)    Metabolic Immuno-Oncology  (21)    Metastasis Process  (15)    Methylation  (33)    Microbiome and Responses to Cancer Therapy  (10)    Monoclonal Immunotherapy  (29)    mtDNA  (13)    Oxidative phosphorylation  (56)    Pancreatic cancer  (10)    Pyruvate Kinase  (27)    The NCI Formulary  (1)    tumor microenvironment  (16)    Warburg effect  (50) Cancer Informatics  (104) Cancer Prevention: Research & Programs  (132) Cancer Screening  (108) Cancer Vaccines: Targeting Cancer Genes for Immunotherapy  (30)    Engineering Enhanced Cancer Vaccines  (3) cancer-general  (7) Cardiac and Cardiovascular Surgical Procedures  (328)    Aortic Valve: TAVR, TAVI vs Open Heart Surgery  (91)       Prosthesis-Patient Mismatch (PPM) in TAVI vs SAVR  (2)       TAVI vs Open Heart Surgery  (6)       Transcatheter Aortic Valve Replacement via the Transcarotid Access  (3)       Transcaval TAVR Procedure  (3)       Valve-in-Valve Procedure  (5)    Atrial Fibrilation (a-Fib), Cardiac Pacing and Arrhythmias  (18)    BackBeat’s Cardiac Neuromodulation Therapy (CNT) bioelectronic therapy  (1)    CABG  (47)    Cancer Surgery of the Heart  (10)    Cardiovascular Fluid Management: algorithms  (1)    Heart Transplant  (16)    Heart-Lung Transplant  (11)    Implantation  (3)    Left Main Coronary Artery Disease (LMCAD)  (3)    Mechanical Assist Devices: LVAD, RVAD, BiVAD, Artificial Heart  (22)    Mitral Valve: Repair and Replacement  (64)       TMVR – Transcatheter Mitral Valve Repair  (5)    PCI  (108)       Bioresorbable Vascular Scaffold (BVS)  (4)       Invasive FFR for PCI  (2)       Multivessel PCI FFR Guidance  (1)       Robotic-assisted percutaneous coronary intervention  (2)       Stent Retriever in endovascular thrombectomy  (3)    Peripheral Arterial Disease & Peripheral Vascular Surgery  (65)       Abdominal Aorta  (20)       Carotid Artery  (15)       Limb ischemia  (4)       Thoracic Aorta  (16)    Pulmonary Valve Replacement and Repair  (3)    Renal Denervation  (20)    Replacement  (1)    Robotically assisted Cardiothoracic Surgery  (2)    Tricuspid Valve Repair  (7)    Vena Caval Filters: Device for Prevention of Pulmonary Embolism and Thrombosis  (2) Cardiovascular Pharmacogenomics  (171) Cargo  (3) Cell Biology  (323) Cell Biology, Signaling & Cell Circuits  (672)    Apoptosis  (17)    Autophagy-Modulating Proteins  (6)    “Antibody–enzyme conjugates”  (6)    Cell Processing System in Cell Therapy Process Development  (27)    Endoplasmic reticulum  (3)    Enzymatic mechanism underlying the synthesis of adenosine triphosphate (ATP)  (3)    Ubiquitin  (11) Cerebrovascular and Neurodegenerative Diseases  (123)    Stroke  (9) Chemical Biology and its relations to Metabolic Disease  (464)    #BIGAxisSummit  (1)    Gut Microbiome and Obesity  (8) Chemical Genetics  (350) Child and Adolescent Psychiatry  (13) Childhood cancer  (17) Childhood malnutrition  (3) children  (4) Circulating Progenitor Cells  (27)    Bone marrow derived cells  (17)    Endothelial cells  (7)    Umbilical cord cells  (6) Clinical & Translational  (239) Clinical Diagnostics  (220)    Mass automation of plasma proteins  (13) Clinical Genomics  (144) Coagulation Therapy and Internal Bleeding  (83) Cognition  (47) Commercialization  (20) Components and IRB related issues  (4) Computational Biology/Systems and Bioinformatics  (470)    Computational Histopathology  (3)    Meta-analysis of transcriptome data  (10) Conference Coverage with Social Media  (494)    MassBio  (3) coronavirus  (18) COVID-19  (20) CRISPR/Cas9 & Gene Editing  (192)    CRISPR alternative for editing genes without cutting  (14)       CAST – Alternative to CRISPR/Cas9  (3)       Transposon-encoded CRISPR–Cas systems direct RNA-guided DNA integration  (4)    CRISPR applied to Human Germ Line  (13)       Gene Editing Impact on Longevity  (6) CT  (20) Cytokines  (21) Cytoskeleton  (85) Developmental biology  (107) Diabetes Mellitus  (146)    Artificial Pancreas for Type 2 Diabetes  (4)    Artificial Pancreas for Type1 Diabetes  (8)    Gestational diabetes  (5) Diagnostic Immunology  (61) Diagnostics and Lab Tests  (128)    Liquid Biopsy: Circulating Tumor Cells in Urine and Blood  (9) Digital HealthCare – biotech & internet joint ventures  (47) Disease Biology  (334) Disease Biology, Small Molecules in Development of Therapeutic Drugs  (488) DNA repair  (73)    Apoptosis  (13)    Autophagy  (13)    Cell death pathways  (19)    Proteolysis  (8)    Proteosome  (8) Drug Delivery Platform Technology  (159)    Drug Carrier Design  (21)       Medication Remote Compliance Monitoring  (3)    Exosomes: Natural Carriers for siRNA Delivery  (9) Drug Toxicity  (74) Ecosystems & Industrial Concentration in the Medical Device Sector  (172)    Cardiac & Vascular Repair Tools Subsegment  (128)    Exec Compensation in the Cardiac & Vascular Repair Tools Subsegment  (14)    Massachusetts Niche Suppliers and National Leaders  (20) Electronic Health Record  (10) Embryology  (24) Empathy  (6) Endocrine Diseases  (60) Enzyme Induction  (46)    ion-transporting enzyme  (2)    K + -ATPase.  (1)    Na +  (2) Epigenetics and Environmental Factors  (35) Ethics and Leadership  (10) Executive Compensation – Big Pharma  (3) Fat soluble vitamins  (4) FDA  (72) FDA Regulatory Affairs  (359)    FDA, CE Mark & Global Regulatory Affairs: process management and strategic planning – GCP, GLP, ISO 14155  (52)    ISO 10993 for Product Registration: FDA & CE Mark for Development of Medical Devices and Diagnostics  (30) Fetal Ultrasound  (2) Fiction and medicine  (5) Frontiers in Cardiology and Cardiovascular Disorders  (929)    Acute Myocardial Infarction  (63)       Cardiogenic Shock  (5)    Anemia in CVD Patients  (6)    Cardio-Oncology  (4)    Cardiomyopathy  (57)    Cardiovascular Research  (187)       Myocardial metabolism, Myocardial ischemia, myocardial perfusion, Myocardial adenine nucleotide metabolism  (64)       Pre-Clinical Animal Model Development  (23)    Chronic Thromboembolic Pulmonary Hypertension (CTEPH) and Pulmonary Arterial Hypertension (PAH)  (20)    Cost of Inpatient Stay for Cardiovascular Diagnosis for Admission  (1)    Electrophysiology  (111)       Ablation Procedure vs Drug Therapy  (2)       Arrhythmia Detection with Machine Learning Algorithms  (7)       Cardiotoxic Risks of Immune Checkpoint Inhibitors  (1)       Genomic Analysis of EKG Electrophysiology Genomics  (3)       implantable cardioverter defibrillator (ICD) and External Defibrillation  (1)       implantable pacemaker  (2)       Rare heart rhythm disorders and Long QT syndrome (LQTS)  (7)    Epigenetics and Cardiovascular Risks  (57)    Heart Failure (HF)  (51)       Acute coronary syndrome  (7)       congestive heart failure  (19)       Hypertensive Disorders of Pregnancy  (1)    Medical Devices R&D and Inventions  (212)       Assist Devices: LV  (3)       RV  (1)       Stents & Tools  (90)       Valves & Tools  (67)    Origins of Cardiovascular Disease  (422)       Atherogenic Processes & Pathology  (180)       Congenital Heart Disease  (34)          Genetic Mutations in Congenital Heart Disease  (4)       inflammation independent of lipid levels  (13)       Systemic Inflammatory Diseases as CVD Risk  (12)    Pharmacotherapy of Cardiovascular Disease  (356)       HTN  (176)       HTN in Youth  (8)       Resident-cell-based  (43)       Subarachnoid Hemorrhage (SAH)  (1)       Transthyretin amyloid cardiomyopathy (ATTR-CM)  (1)    Spontaneous Coronary Artery Dissection (SCAD)  (6)    Stroke  (15)       endovascular thrombectomy  (6)    Vascular Diseases  (21)       mesenteric ischemia  (3) Future Pandemics Inform-graphics  (1) Gastroenterology  (38) Gene Regulation  (233) Gene Regulation and Evolution  (137) Genetics & Innovations in Treatment  (176) Genetics & Pharmaceutical  (204) Genome Biology  (967)    Exosomes  (25)    Gene Therapy & Gene Editing Development  (42)    mRNA Therapeutics  (20)    Mutagenesis  (27)    Single Cell Genomics  (25)    Single-cell sequencing  (20)    Variation in human protein-coding regions  (35) Genomic Endocrinology  (42) Genomic Testing: Methodology for Diagnosis  (416) Genomics Pharmacy  (40) Global Market of Medical Devices Technology  (3) Global Medical Publishers by Country  (3) Global Partnering & Biotech Investment  (48) GLP  (4) Glycobiology: Biopharmaceutical Production  (16) Glycobiology: Biopharmaceutical Production, Pharmacodynamics and Pharmacokinetics  (28) Health Care System by Country  (58)    AI Models in Healthcare  (12)    Centers for Medicare & Medicaid Services  (8)    Health in Israel  (2)    India  (1)    United States  (27)       Hospital-based Medical Innovations  (10)       Medical Recertification and Maintenance of Certification (MOC)  (1) Health Economics and Outcomes Research  (384)    Women Health  (18)       Heart and Brain Disease in Women  (3) Health Law & Patient Safety  (165)    and Bioethics  (14)    Biotechnology  (12)    Health Law Policy  (13) HealthCare IT  (139) Healthcare Reform  (118)    Accountable Care Organizations  (26)    Affordable Care Act  (29)       Repair  (1)       Repeal ACA  (1)       Replace  (1)    Federal Budget Appropriations  (27)    Healthcare costs and reimbursement  (59)    Indigent Nutrition  (14)    Medicare and Medicaid  (20)    Prescription Drugs Costs  (21)    Skilled Nursing Facilities  (6)    Technology Capital Expenses  (15)    Uninsured and Underinsured  (20) Hematology  (100)    Acute lymphocytic leukemia  (18)    Acute myelocytic leukemia  (21)    Hematopoiesis  (48)    Lymphoma  (21) History and physical exam  (6) Human aging  (27) Human Immune System in Health and in Disease  (246) Human Sensation and Cellular Transduction: Physiology and Therapeutics  (21) Image Processing/Computing  (41) Imaging-based Cancer Patient Management  (116) Immuno-Oncology & Genomics  (133)    mRNA platform in Drug DIscovery  (6) Immunodiagnostics  (141)    Cancer-Immune Interactions  (31)    CNS-Immune Interface  (5)    Neuronal Circuits  (4) Immunology  (123)    Adaptive Immune Response to Biomaterials and Tissue Repair  (13)    Antibody Responses Predict Antigen Exposure  (17)    Cytokine Receptor Structure  (8)    Human Antibody Response  (18)    Human Circulating Antibody Repertoire  (11)    Human Naive B Cell Repertoire  (8)    MHC Repertoires for Antigen Prediction  (8)    Protection Against Autoimmune Disease  (11)    Synthetic Immunology: Hacking Immune Cells  (15) Immunotherapy  (136)    CAR-T  (16)    combination immunotherapies.  (15)    Efficacy of Anti-Tumor T Cells  (15)    Engineering Better T Cells  (10)    Immune Engineering  (18)    Immune Modulatory  (16)    Integrin-targeted Combination Immunotherapy  (6)    Modulating Macrophages in Cancer Immunotherapy  (17)    NK Cell-Based Cancer Immunotherapy  (20)    Synergistic Innate and Adaptive Immunotherapy  (14) Income Disparity  (2) Infectious Disease & New Antibiotic Targets  (162)    Antibiotic resistance  (7)    Viral diseases  (37)       Myocarditis  (1) Infectious Disease Immunodiagnostics  (58)    Virology – Vector-borne DIsease  (17) Inflammasome  (29)    Anti-tumor necrosis factor drugs (TNF inhibitors)  (3) Innovation in Immunology Diagnostics  (111)    Universal Immune Cell Therapies (uICT)  (11) Innovations  (186)    R&D Expenditure  (8) Innovations in Neurophysiology & Neuropsychology  (145)    Age and Life Expectancy  (3)    autism spectrum disorder  (1)    Circadian Rhythm and Sleep  (6)    hNPCs  (1)    Nervous System Function  (2)    Relapsing Multiple Sclerosis  (1) Intellectual Property  (85)    Disputes and Settlements  (9)    IP Valuation Models – Pricing Intangible Assets  (7)    Patent Law in Biotech  (12) Intellectual Property, Innovations, Commercialization, Investment in technological breakthrough  (121) International Global Work in Pharmaceutical  (191) Interventional Oncology: Radiofrequency Ablation, Transarterial Chemoembolization, Microwave Ablation and Irreversible Electroporation (IRE)  (12) Interviews with Scientific Leaders  (319)    Albany Medical Center Prize in Medicine and Biomedical Research  (3)    Annual Breakthrough Prize  (4)    Annual Lewis S. Rosenstiel Award  (2)    Awards in Cardiology and Cardiovascular Medicine  (6)    CEOs of Biotech Companies  (3)    Gerald D Aurbach Award for Outstanding Translational Research  (2)    Interviews with Key Opinion Leaders (KOLs)  (11)    James Prize in Science and Technology Integration  (2)    Jessie Stevenson Kovalenko Medal – Medical Sciences  (2)    Lemelson-MIT Prize  (2)    Life Sciences Breakthrough Prize  (6)    Mosteller Statistician of the Year Award  (2)    Mourning the Loss of a Scientific Leader  (6)    National Academy of Sciences AWARDS  (4)    Nobel Prize Winners  (30)    Noble Prize (Not Nobel Prize)  (2)    Paul Marks Prize for Cancer Research  (2)    Russ Prize recognizes bioengineering achievements worldwide  (2)    The Dan David Prize  (6)    Warren Alpert Foundation Prize Recipients  (4)    Wolf Prize  (2)    Wolf Prize in Medicine  (2)    women in science  (5) Investment in Technological Breakthrough  (60) Ionic Transporters Na+  (25) IP Development by LPBI Group Team  (14) IP Development by LPBI Group Team & Other Organizations  (8) ISO 14155  (3) Joint Venture – SBH & M3DP: SOP and Arrangements  (1) Justice & Law  (1) K  (15) Lab-on-a-chip  (2) Landscape  (1) Lasers and photonics  (18)    Midrange IR spectroscopy  (1) Law and Medicine Conflicts  (15) Leadership, Power, Social Interlocking Connections  (13) Lipid metabolism  (109)    Fatty acids  (38)    Lipids  (38)    PCSK9 Inhibitor Therapy  (19) Lipidomics  (11) Liposome  (4) Liver & Digestive Diseases Research  (122) LPBI Group, e-Scientific Media, DFP, R&D-M3DP, R&D-Drug Discovery, US Patents: SOPs and Team Management  (143)    Award Nominations  (5)    BioMed e-Books e-Series by LPBI Group  (9)    Feedback from Investors: LPBI Portfolio of Five Businesses  (2)    LPBI Group Founder – Aviva Lev-Ari  (27)    PhD  (1)    RN  (1) LPBI Management  (23) Massachusetts Academy of Sciences (MAS)    (2) Materials Science & Engineering  (37)    Organic BioElectronics  (2) Math  (13)    Great Discoveries  (7) Mechanical Assist Devices: LVAD  (4) Medical and Population Genetics  (193) Medical Devices R&D Investment  (242)    21st Century Cures Act  (2)    CE Mark & Global Regulatory Affairs: process management and strategic planning – GCP  (14)    Rhythm management device hardware: dual-chamber pacemakers  (1)       Systolic HTN  (1) Medical Imaging Technology  (59) Medical Imaging Technology, Image Processing/Computing, MRI, CT, Nuclear Medicine, Ultra Sound  (164)    Circumferential-Intravascular-Radioluminescence-Photoacoustic-Imaging (CIRPI)  (3)    Echocardiography  (3)    MRI  (18)    Noninvasive Diagnostic Fractional Flow Reserve (FFR) CT  (6)    Ultra Sound  (10) Melatonin & Circadian Regulation  (9) memory loss  (1) Metabolism  (239)    Biochemical pathways  (144)       Enzymes and isoenzymes  (73)          Dehydrogenase  (16)          Kinase  (28)          Phosphatase  (9)          Phosphorylase  (22)          tyrosine decarboxylases  (3)    Inosine nucleotides  (9)    Leloir pathway  (6)    microbiome  (7)    Pentose monophosphate shunt  (14)    Pyridine nucleotides  (28)       Pyridine nucleotide transhydrogenase  (7) Metabolomics  (321) Methods  (37) Mg++  (10) Microbiologial genetics  (36) Microbiology  (68)    Virology  (14) Micronutrients  (16) Microvesicle  (7) Microwave Ablation and Irreversible Electroporation (IRE)  (1) Mobile Healthcare  (5) Molecular Genetics & Pharmaceutical  (377)    Organoids  (3) Monoclonal antibody therapy  (14) Mutant Gene Expression  (42) Myocardial adenine nucleotide metabolism  (6) Myocardial Ischemia  (26) Myocardial Metabolism  (36) Na-K transport  (40) Na-K-ATPase  (27) Nanotechnology for Drug Delivery  (99) Nephrology  (46) Nephrology & Regenerative medicine  (9) Neurodegenerative Diseases  (89)    hNPCs  (3)    MS  (5) Neurohumoral Transmission  (68)    Ca2+ triggered activation  (21)    Calmodulin  (13)    Parkinson’s disease dyskinesia levodopa  (3)    PKC  (13)    Synaptic vesicle  (20) Neurological Diseases  (121) Neuroscience  (126) Next Generation Sequencing (NGS)  (27)    Nanopore sequencing  (1) NIH Common Fund  (1) Nitric Oxide in Health and Disease  (136) Nuclear Medicine  (11) Nutrigenomics  (68) Nutrition  (195)    Nutritional Supplements: Atherogenesis, lipid metabolism  (50) Nutrition and Phytochemistry  (62)    Minerals in Medicine  (4)    Plant extract  (22) Nutrition Disorders  (31) Nutritional Supplements: Atherogenesis  (31) Obesity  (19) Oligonucleotide Therapeutics & Delivery  (7) Oncolytic virus & OncoViro-Therapy  (23)    Synthetic Virology  (1) Organ-on-a-Chip & 3D Printing in Life Sciences  (7) Pain: Etiology, Genetics & Innovations in Treatment  (24) Parasitology  (5)    Malaria  (4)    Tropical diseases  (1) Patents  (35) Patient Experience  (66)    Art therapy  (1)    Hospital reputation  (7)    Humor  (1)    Music therapy  (2)    Pain Alleviation  (7)    Patient Outlook  (28)    Reputation of Interventionist  (4)    Support Staff  (13)    Supportive therapies  (6)       laughfter  (1)    Surgical Procedure  (9) Patient Experience: Personal Memories of Invasive Medical Intervantion  (30) Patient’s Voice: Personal Experience with Invasive Medical Procedures  (18) Perioperative Statins at Noncardiac Surgery  (2) Personal Health Applications: Tech Innovations serves HealhCare  (43) Personalized and Precision Medicine & Genomic Research  (739)    Longevity  (3)    New Drug Approval  (6)    Patient-centered Medicine  (39)       cell-based therapy  (9)       stem cell biology and patient-specific  (7)    Personalized Medicine Coalition  (10)    Precision Cancer Medicine  (33) Phagophore  (2) Pharmaceutical Analytics  (261)    Pharmacologic toxicities  (62) Pharmaceutical Discovery  (111)    Rapid automation of plasma protein pools  (18) Pharmaceutical Drug Discovery  (206)    Drug Development Process  (61)       Drug Discovery Chemistry  (33)    drug repurposing  (11) Pharmaceutical Industry Competitive Intelligence  (346)    Pharmacovigilance  (7)    Value-based Drug Pricing  (8) Pharmaceutical R&D Informatics  (45) Pharmaceutical R&D Investment  (301) Pharmacodynamics and Pharmacokinetics  (24) Pharmacogenomics  (161) Photography Collection  (1) Physics  (12) Placenta  (7) Population genetics  (27) Population Health Management  (205)    Evolution of Biology Through Culture  (14)    U.S. Employment-to-Population Ratio  (8) Population Health Management, Genetics & Pharmaceutical  (643)    COVID-19  (157)       Biomarkers: Inflammation  (37)       Cancer Researchers Fighting COVID-19  (14)       COVID-19 effects on Human Heart  (15)       COVID-19: Pandemic Surgery Guidance  (19)       Economic Impact of Coronavirus Pandemic  (41)       number of asymptomatic infections  (27)       Treatment Protocols for COVID-19  (62)    SARS-CoV-2  (141)       Coronavirus Gene Expression  (66)          SARS-CoV-2 circulating variants   (14)          SARS-CoV-2 Viral Variants  (19)       Glycosylation and its Role in SARS-CoV-2 Viral Pathogenesis  (2)       Immune-Mediation (independent immunopathology: lung and reticuloendothelial system)  (30)       Mechanisms of infection by SARS-CoV-2  (21)       SAR-Cov-2 a vasculotropic (blood vessels) RNA Virus  (35)          SARS-COV2 Hijacking the Complement and Coagulation Systems  (19)       Seasonality & Environmental Factors in Resurgence  (26)       Serology tests for coronavirus antibodies  (44)       T-cell response to SARS-CoV-2 infection  (14)       Vaccinology  (51)          Mechanism of Thrombosis with AZ & J&J COVID-19 Vaccines  (5)       Virtual Drug Molecule Screening targeting SAR-CoV-2 proteins  (8)    Virus Infective Acute Respiratory Syndrome: SARS-CoV  (92) Population Health Management, Nutrition and Phytochemistry  (162) Preimplantation Genetic Diagnosis and Reproductive Genomics  (13) Protein-energy malnutrition  (12) Proteomics  (367)    Amino acids  (54)    Proteins  (138) Pulmonary diseases  (16)    Lung and pulmonology  (15) Pulmonary pathology  (8) Radio Frequency (RF)-based Surgical Solutions  (2) REAL TIME Conference Coverage Twitter’s Hashtags and Handles per Presentation/session  (50) Regenerative Biology and Medicine  (92) Regulated Clinical Trials: Design, Methods, Components and IRB related issues  (265) Reproductive Andrology, Embryology, Genomic Endocrinology, Preimplantation Genetic Diagnosis and Reproductive Genomics  (113) Reproductive Biology & Bio Instrumentation  (78) RNA Biology  (81)    RNA interference (RNAi) therapeutic  (4) RNA Biology, Cancer and Therapeutics  (64) RVAD  (1) SBIR, SBA, NIH, NSF  (3) Schizophrenia  (16) Scientific & Biotech Conferences: Press Coverage  (182) Scientific Publishing  (609)    Curation  (585)       Curation methodology  (40)       De novo synthesis  (16)       Dialectic  (17)       Discovery process  (72)       Evolutionary cognition  (52)       Experimental validation  (91)       Explanatory  (91)       Historical relevance  (71)       Technology Advance Assessment of  (69)       Theoretic convergence  (27)    Open Access Journals  (37) Scientist: Career considerations  (198)    Big Data & Analytics  (17)    Data Science  (13)    Women in Life Sciences  (12) Scoop.it  (19) Sensors & Analytics  (18) Sepsis  (2) Severe Autism  (3) Signaling  (102)    Phosphorylation  (43)    S-nitrosylation  (13)    Ubiquitinylation  (34) Signaling & Cell Circuits  (130) single cell sequencing  (3) Small Molecules in Development of Therapeutic Drugs  (71) Social Development  (15) Specialized 3D BioPrinters (Cornea  (1) Statistical Methods for Research Evaluation  (137) Stem Cells for Regenerative Medicine  (177)    Cardiac muscle regeneration  (19)    Competition in regenerative stem cell science  (18)    Human neural progenitor cells  (8)    Skeletal muscle regeneration  (9) STORM  (2) Stress Disorders  (19) Substance Abuse  (4) Systemic Inflammatory Response Related Disorders  (161)    Inflammatory Pathophysiology  (9) Technology Transfer: Biotech and Pharmaceutical  (354) therapeutics  (3) Tissue Engineering and Regenerative Medicine  (22) Tissue Microenvironment  (5) Transarterial Chemoembolization  (2) Transcriptomics  (47) Transformative Technologies in Healthcare  (23) Translational Science  (230)    Best evidence  (52)    Bias measurement tools  (2)    Evidence-based decision-making  (29)    Inferential analysis  (25)    Intra-rater error  (1)    Quality Assurance  (8)    Random Error  (2)    Systematic Error (Bias)  (6)    Total error  (2)    Translational Effectiveness  (49)    Translational Research  (92) Trends in Global Economy  (6) Uncategorized  (1,019) Unfolded Protein Response (UPR)  (6) US and Global Economy: Trends and Findings  (9) Venture Capital  (47)    Income Geographic Distribution  (3)    Institutional Capital Raised by Female Founders  (6) virology  (10) Vision  (7) Voices of Patients and Healthcare Providers  (22) Water Transporters  (8) Wearable Tech + Digital Health  (5) Anemia  (22) Neutropenia  (8) Neutrophilia  (9) Platelet count disorder  (9) Folate and B12  (7) Iron deficiency  (5) Myelodysplasia  (13) Myelofibrosis  (10)

• Meta

  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org

• • 2012pharmaceutical
  • sjwilliamspa